Pet Imaging Of Early Therapeutic Response In Solid Tumors by Blocker, Stephanie J.
Wayne State University
Wayne State University Dissertations
1-1-2017
Pet Imaging Of Early Therapeutic Response In
Solid Tumors
Stephanie J. Blocker
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Bioimaging and Biomedical Optics Commons, Biology Commons, and the Oncology
Commons
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Blocker, Stephanie J., "Pet Imaging Of Early Therapeutic Response In Solid Tumors" (2017). Wayne State University Dissertations. 1785.
https://digitalcommons.wayne.edu/oa_dissertations/1785
 
 
 
 
PET IMAGING OF EARLY THERAPEUTIC RESPONSE IN SOLID TUMORS 
by 
STEPHANIE J BLOCKER 
DISSERTATION 
Submitted to the Graduate School 
of Wayne State University, 
Detroit, Michigan 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
2017 
      MAJOR: CANCER BIOLOGY 
      Approved By: 
     ___________________________________ 
      Advisor     Date 
     ___________________________________ 
     ___________________________________ 
     ___________________________________ 
     ___________________________________ 
 
 
 
 
 
ii 
 
DEDICATION 
 
To my father, mother, and sister. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
 With the completion of my dissertation work, there are a great deal of people who 
deserve my appreciation.  The work I have accomplished, as well as all of the knowledge 
I have gained, would not have been possible without the support of my advisors, my 
colleagues, my family, and my friends. 
Advisor 
 I would like to express my sincere gratitude to Dr. Anthony Shields, who has served 
as my advisor during my dissertation work.  Along with providing an environment in which 
I could learn, design projects, and hone my skills, Dr. Shields also encouraged me to 
develop creative problem solving skills.  His ever-inspired approach to solving scientific 
problems has taught me how to ask questions, to thoughtfully tackle problems, and to see 
the big picture that is often obscured by details.  I thank Dr. Shields for his unwavering 
support as a mentor, and for serving as a model of scientific integrity that I will strive to 
match throughout my career. 
Dissertation Committee 
 Throughout my dissertation research, I have received encouragement and 
mentorship from each of the members of my Dissertation Committee.  Each member has 
provided me with valuable insight, and encouraged my ideas as they developed.  Dr. 
Nerissa Viola has been an invaluable source of knowledge, information, and inspiration 
regarding all imaging aspect of my projects, and has helped me navigate the logistical 
hurdles that lie between concept and completion.  Dr. Olivia Merkel has consistently 
asked thoughtful questions which allowed me to see my projects from multiple 
perspectives, and has proposed inventive solutions for difficult problems.  Dr. David 
 
 
iv 
 
Gorski has provided vital insight into the biology and design of multiple facets of these 
projects, and has encouraged me to seek and understand the clinical implications of my 
results.  Dr. Joshua Reineke, despite being in another state, continues to provide a wealth 
of information and expertise on the chemistry and engineering of many of the elements 
of my projects.  Each of my committee members has provided me with valuable 
mentorship and consistent encouragement, for which I am especially grateful. 
Shields Lab 
 Each member of the Shields team has been a great source of support for me during 
the entire time in the lab.  I would like to thank Kirk Douglas for his contributions to my 
projects and my education, of which there are too many to list.  Kirk not only helped me 
navigate the difficult logistics of setting up my studies, but he also helped me to complete 
them—all while being a great friend, particularly during the most stressful times.  I want 
to acknowledge Jawana Lawhorne-Crews for teaching me the basics of image analysis 
and imaging study design.  Her advice was essential, as I had no experience in the field 
upon joining the lab.  I would also like to sincerely thank Janice Akoury, for her unwavering 
dedication to helping me navigate the uncertainties of graduate school.  I am unable to 
count the number of pitfalls and disasters I avoided thanks to her brilliant problem-solving 
and foresight.  Also, I want to acknowledge former lab member, Dr. Omid Tahrani, whose 
work in the Shields Lab provided the rationale for a large part of my dissertation.  Finally, 
I would like to thank Enxhi Lalo, an undergraduate student at Michigan State University 
whom I had the pleasure to mentor for three summers.  Enxhi’s dedication to learning and 
his interest in clinical science made for a great partnership, and the work he completed 
during his time in the lab has been an important addition to the Shields Lab. 
 
 
v 
 
Cancer Biology Graduate Program 
 Of course, I must mention the Cancer Biology Graduate Program, and the integral 
role its administration has played in my accomplishments thus far.  I would like to thank 
Dr. Larry Matherly for his personal vested interest in the success of the students in the 
CB program.  His guidance was instrumental in helping me to get the most out of my 
experience at Wayne State.  To Dr. George Brush, I would like to offer my thanks for all 
of the input and advice he has provided over the years.  I would like to thank Nadia Daniel, 
for her never-ending enthusiasm for the CB students and for ensuring that we were 
always connected to the resources we needed to succeed.  Additionally, I would like to 
thank the members of the Cancer Biology Steering Committee for fostering a student 
research-focused environment for the program and its students to flourish. 
Additional Significant Support 
 I would like to specifically thank Dr. Lisa Polin and her lab for all of the guidance, 
assistance, and expertise she offered over the years.  I credit the efficiency of our animal 
studies to her expert input, without which we likely would have had fewer, more arduous 
successes.  Staff members of her lab, Juiwanna Kushner and Katherine White, were 
persistently helpful as well during our studies, and their input was always appreciated. 
 I want to specifically acknowledge Karri Stark, who was my unofficial mentor in all 
aspects of in vitro work.  Her unmatched skillset, ability to pinpoint problems, and 
dedication to all things science were the foundations on which I was able to learn a large 
portion of my bench skills.  I thank Karri for serving as a role model for me as I continue 
to work and learn. 
 
 
vi 
 
 During my collaboration with Merrimack Pharmaceuticals, I was able to work with 
many great scientists out of Boston.  I would like to thank Dr. Helen Lee and Dr. Bart 
Hendriks for their persistent support of my project, and for their continued input and 
advice.  In particular, I would like to specifically thank Helen for always responding quickly 
and beyond sufficiently each time I asked a question. 
 During our animal imaging studies, I had the opportunity to work with Dr. Xin Lu, 
who often offered his support and expertise.  I would like to thank him for his help with 
the microPET instrumentation and data configuration, as well as his insight into the data 
analysis. 
 I would also like to thank Dr. Tom Mangner, for synthesizing the 18F-FMAU for all 
of the lung studies.  Without his hard work, none of those studies would have been 
possible. 
Family and Friends 
 Aside from the amazing support I have received from mentors and colleagues, 
none of my accomplishments to date would have been possible if not for the steadfast 
support of my family.  I want to give my most heartfelt thanks to them for everything they 
have done to keep me motivated and calm throughout this process.  I thank my dad, who 
has always been confident in my ability to do great things—even when I wasn’t sure, 
myself.  He has never let his daughters forget that he believes in us, and that has always 
helped me to push through the tougher times.  I thank my mom, who taught me everything 
I know about being a strong, intelligent woman.  She has always been a fierce advocate 
for her daughters, and is always ready to help, no matter what the issue.  I thank my 
sister, Jillian, who has taught me the value of keeping perspective, and taking time to 
 
 
vii 
 
laugh.  Despite being my younger sister, I feel that she has taught me so much about how 
to identify the important things in life.  My family’s support has never faltered, and I hope 
to make them proud as I move forward. 
 I would also like to thank my husband, Alex Duric.  Having met in the lab, Alex 
often understood the frustrations I would often experience with my projects, and was 
always able to suggest something helpful.  Throughout my dissertation work, he has 
helped me to grow as a person, and is the single largest contributor to my confidence.  I 
want to thank him for keeping me grounded, while encouraging my dreams to take flight.  
I also want to thank Alex’s parents, who have very quickly become wonderful additions to 
my family and are always very supportive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
TABLE OF CONTENTS 
Dedication…………………………………………………………………….…. ii 
Acknowledgements…………………………………….…………….…….…… iii 
List of Tables…………………………………………………………….….…… x 
List of Figures…………………………………………………………….……… xi 
List of Abbreviations…………………………………………………………….. xiii 
Chapter 1 – Introduction  
1. Basic PET Physics and Tracer Synthesis…………………….................. 1 
1.1 Biological Implications of PET Interpretation…………………................. 3 
2. PET for Early Detection of Therapeutic Effects on Solid Tumors……… 5 
3. Imaging of Nanoparticle Distribution to Assess Treatments that Alter 
Delivery……………………………………………………………………..... 7 
3.1 Imaging the Effects of Targeting Tumor Angiogenesis on NP 
Deposition in Solid Tumors……………………………………...…………. 15 
3.1.1  Anti-VEGF Therapies…………………………………..………………. 16 
3.1.2 Targeting TGF-β………………………………………..……………….. 17 
4. PET with Radiolabeled Pyrimidine Analogs for Early Assessment of 
Drug Efficacy in Tumors…………….……………….……………………... 18 
Chapter 2 - Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on 
Liposomal Delivery to Colon Cancer Xenografts 
 
1. Introduction…………………………………….………………..…………… 23 
2.  Materials and Methods…………………………………………………… 25 
3. Results……………………………………………………………………… 33 
3.1  64Cu-MM-DX-929 PET can detect significant differences in LP 
delivery   between colon tumors treated with bev and untreated 
controls…….………………………………………………………..……..... 33 
3.2   Bevacizumab does not alter systemic distribution of 64Cu-MM-DX-
929 in non-tumor tissues……………………………………………….….. 40 
 
 
ix 
 
3.3   Colon tumor growth was delayed by short-term bev alone, liposomal 
irinotecan alone, or short-term bev followed by liposomal irinotecan..... 42 
3.4   Bev treatment induced measurable changes in tumor blood vessels 
after two injections……………………………..……………………………. 45 
3.5    64Cu-LP do not associate with macrophages and are stable in 
circulation for up to 48 hours.……………………………………………… 48 
4 Discussion…………………………………….………………..……………. 50 
Chapter 3 – 18F-FMAU PET to Evaluate Response to Cisplatin in Pre-
Clinical Lung Cancer Studies 
 
1. Introduction……………….…………………………………………….……. 54 
2. Materials and Methods……………………………………………..………. 56 
3. Results…………………………………….………………..………………... 63 
3.1   Changes in 18F-FMAU uptake in lung tumor cells after cisplatin 
treatment differ based on cisplatin sensitivity………………………......... 63 
3.2   Significant decreases in 18F-FMAU uptake were observed in H460 
xenografts but not H292 xenografts after 24 hours of cisplatin 
treatment in mice…………………………….……………………………… 68 
3.3   Systemic distribution and clearance of 18F-FMAU was not affected by 
cisplatin treatment………………………………….……........................... 74 
3.4   18F-FMAU metabolism was not altered by cisplatin treatment………… 77 
4 Discussion……………………………………………..……………............. 79 
Chapter 4 –Summary…………………………….…………..………………… 82 
References…………………………………….…..…………………………….. 85 
Abstract…………………………………….………..…………………………… 121 
Autobiographical Statement………………………………………..………….. 123 
 
 
 
 
 
 
x 
 
LIST OF TABLES 
Table 1.  Examples of nanoparticle platforms for imaging……………….. 9 
Table 2.  Imaging NPs for measuring therapeutically-altered NP delivery 13 
Table 3.  %64Cu-LP activity in human whole blood associated with 
                blood cell populations……………………………………………... 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF FIGURES 
Figure 1. Liposome animal study design……………………………….. 29 
Figure 2. Changes in SUVmax of HT-29 colon tumors decreased after 
treatment with bev compared to untreated tumors…………. 35 
Figure 3. SUVmax of individual tumors decreased after treatment with 
bev compared to untreated tumors…………………………... 35 
Figure 4. 64Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts 
increases after 7 days without therapeutic intervention……. 36 
Figure 5. 64Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts 
does not increase when treated with two doses of 
bevacizumab……………………………………………………... 37 
Figure 6. Changes in HT-29 tumor SUVmax values measured with  
64Cu-MM-DX-929 PET………………………………………….. 39 
Figure 7. Bev treatment did not change overall biodistribution of 
64Cu-MM-DX-929……………………………………………….. 41 
Figure 8. HT-29 tumor growth is affected by bev, LP-I, and bev followed 
by LP-I compared to untreated controls………………………. 44 
Figure 9. Bev induced significant changes in blood vessel diameter 
early into treatment……………………………………………… 46 
Figure 10. Percentage of total tissue area occupied by CD34 positive 
vessels in untreated and bev treated tumors…………………. 47 
Figure 11. 64Cu-LP are stable in circulation and remain in plasma for at 
least 48 hours……………………………………………………. 49 
Figure 12. Schematic representation of FMAU mouse study design…... 60 
Figure 13. H460 cells are more sensitive to cisplatin-induced cell killing 
than H292 cells………………………………………………….. 65 
Figure 14. After 24 hours of cisplatin treatment 18F-FMAU uptake 
increased in H292 cells but not H460 cells…………………….. 67 
Figure 15. Cisplatin-treated H460 tumors in mice showed significant 
reductions in 18F-FMAU uptake compared to H292 tumors 
imaged with PET…………………………………………………. 70 
 
 
xii 
 
Figure 16. 18F-FMAU PET scans of mice bearing H460 tumors before 
and after cisplatin treatment…….……………………………... 72 
Figure 17. 18F-FMAU PET scans of mice bearing H460 tumors before 
and after cisplatin treatment………….………………………... 73 
Figure 18. Cisplatin treatment did not alter clearance or biodistribution 
of 18F-FMAU in mice…………………………………………… 76 
Figure 19. 18F-FMAU metabolites represent a negligible fraction of  
18F-FMAU detected in the blood and are not significantly 
altered by cisplatin treatment…………………………………… 78 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
LIST OF ABBREVIATIONS 
%i.d. Percent injected dose 
%i.d./cc Percent injected dose per gram 
%ΔSUVmax Percent change in maximum Standardized Uptake Value 
µCi Microcurie 
µm Micrometer 
µmol Micromole 
18F Fluorine-18 
2q7d Two doses per week 
5FU 5-fluorouracil 
64Cu Copper-64 
99Tc Technetium-99  
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
Bev bevacizumab (Avastin™) 
Bq Becquerel 
Cc Cubic centimeter; gram 
CD31 Cluster of differentiation 31 
CD34 Cluster of differentiation 34 
Ci Curie 
Cm Centimeter 
CRC Colorectal cancer 
CT Computerized Tomography 
 
 
xiv 
 
DCE-MRI Dynamic contrast-enhanced magnetic resonance imaging 
DNA Deoxyribonucleic acid 
Dox Doxorubicin 
Dpm Disintegrations per minute 
DTPA Diethylenetriaminepentaacetic acid or pentetic acid 
Dx-NP Diagnostic Nanoparticles 
ECM Extracellular matrix 
EPR Enhanced permeability and retention 
FAU 1’-(2’-deoxy-2’-fluoro-beta-D-arabinofuranosyl)uracil 
FDG Fluorodeoxyglucose 
FIAU 2’-fluoro-2’-deoxy-1-beta-D-arabinofuranosyl-5-iodo-uracil 
FLT Fluorothymidine 
FMAU 1’-(2’-deoxy-2’-fluoro-beta-D-arabinofuranosyl)thymine 
G Gram 
Gd Gadolinium 
HBS HEPES-buffered saline 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HER2 Human epidermal growth factor receptor 2 
HPLC High-pressure liquid chromatography 
HPMA N-(2-Hydroxypropyl)methacrylamide 
IACUC Institutional Animal Care and Use Committee 
IC50 Half maximal inhibitory concentration 
IFP Interstitial fluid pressure 
 
 
xv 
 
IP Intraperitoneal 
iTLC Instant thin layer chromatography 
IV Intravenous 
kBq kiloBecquerel 
kBq/cc kiloBecquerel/gram 
keV Kiloelectronvolt 
Kg Kilogram 
KOH Potassium hydroxide 
Kps Transfer coefficient 
LP Liposome(s) 
LP-I Liposomal irinotecan 
M Molar 
mCRC Metastatic colorectal cancer 
Mg Milligrams 
Mg Milligram 
Ml Milliliter 
Mm Millimeter 
mM Millimolar 
Mm Millimeter 
MR Magnetic resonance 
MRI Magnetic Resonance Imaging 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
MVD Microvessel density 
 
 
xvi 
 
NaOAc Sodium acetate 
NiR Near infrared 
Nm Nanometer 
NP Nanoparticle(s) 
PBS Phosphate buffered saline 
PEG Polyethyline glycol 
PET Positron Emission Tomography 
RBC Red blood cell 
RNA Ribonucleic acid 
ROI Region of Interest 
RPMI-1640 Roswell Park Memorial Institute-1640 
Rx Drug 
S phase Synthesis phase 
SCID Severe Combined Immunodeficiency 
SD Standard deviation 
SPECT Single Photon Emission Computerized Tomography 
SUV Standardized Uptake Value 
SUVmax Maximum Standardized Uptake Value 
t½  Half-life 
TK1 Thymidine Kinase 1 
TK2 Thymidine Kinase 2 
Tx-NP Therapeutic Nanoparticles 
VEGF Vascular endothelial growth factor 
 
 
xvii 
 
VEGFR Vascular endothelial growth factor receptor 
VOI Volume of Interest 
Δ Change 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1.  INTRODUCTION 
In recent decades, cancer imaging has advanced beyond the determination 
of size and location of lesions to defining the biological properties of tumors.  One 
of the most powerful tools to dynamically measure tumor activity is positron 
emission tomography (PET), a form of nuclear medicine imaging which utilizes 
small doses of radioactive tracers to produce three dimensional images.  While 
PET can provide morphological information about solid tumors, the novelty of PET 
imaging over other modalities is its ability to non-invasively provide information 
about the metabolic behavior of tumors.  This allows both physicians and 
researchers to gain insight into the tumors which may aid in determining the best 
options for treatment, as well as monitor tumor response to therapies.  In this way, 
PET is one of the diagnostic modalities at the forefront of personalized medicine 
for cancer patients. 
1.  Basic PET Physics and Tracer Synthesis 
PET is performed by injection of a radioactive tracer, and scans are 
acquired on by detection of emitted photons.  Tracers for PET are designed to 
incorporate positron emitting nuclides, such as 18F or 64Cu.  Upon decay, positrons 
are released from the nuclide and subsequently collide with an electron in the 
surrounding area.  This collision, or annihilation, releases two photons with 
energies of 511 keV in opposite directions (1).  PET utilizes rings of crystal blocks 
to quantitate emitted photons (2, 3).by detecting coincidence pairs of photons in 
all directions around the object being scanned.  Subsequently, a statistical map of 
describing the probable 3-dimensional location of tracer is generated.    After 
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allowing for distance traveled by the positron prior to annihilation, tissue scatter, 
and coincidental detection of non-paired photons (“random” events), clinical PET 
scanners typically have a spatial resolution of about 4-5 mm (4).  Preclinical PET 
scanners for small animal imaging typically have better resolution, due to the 
smaller diameter of the crystal rings (5, 6).  This leads to resolution of about 1-2 
mm in PET images acquired during small animal imaging (7-9).   Additionally, the 
detection of only 511 keV photons by the PET crystals results in excellent 
sensitivity, often between 10-11 and 10-12 mol/L of tracer required to obtain an 
image (10).  Tracers synthesized for PET often exhibit high specific activity which, 
combined with PET detection sensitivity, allows for image acquisition with a 
relatively small mass of tracer required (2). 
Tracers for PET are be rationally designed to image biological processes of 
interest to acquire valuable biochemical information (11).  Depending on their 
atomic properties, positron emitting nuclides can be incorporated into biologically 
active molecules.  For example, 18F is can be substituted for a hydroxyl group, 
such as at the C-2 position of glucose to form 2-deoxy-2-18F-fluorodeoxyglucose, 
or 18F-FDG (12) .  18F-FDG is thought to be retained in metabolically active tissues 
following uptake mediated by glucose transporter 1, or GLUT1 followed by 
phosphorylation by hexokinase (13).  18F-FDG was one of the first FDA-approved 
tracers for PET for a variety of applications.  It is relatively easy to synthesize, and 
18F is widely available.  In utilizing a glucose analogue, 18F-FDG images can 
identify tissues that are metabolically active, such as brain and heart (14).  
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Additionally, proliferating tumors utilize circulating glucose during cellular 
metabolism. 
Another commonly used tracer in PET is 18F-fluorothymidine, or 18F-FLT.  
18F-FLT is a thymidine analogue that is taken up by cells through the salvage 
pathway of DNA synthesis (15).  Mimicking endogenous thymidine, 18F-FLT is 
trapped in rapidly dividing cells which are rapidly dividing, such as tumor.  Thus, 
18F-FLT serves as a marker of cellular proliferation with PET (16). 
1.1.  Biological Implications of PET Interpretation 
Although the mechanism of tracer quantitation during PET is always 
coincidence detection of 511 keV photons, PET tracers can be designed to image 
a multitude of tissue properties.  As with 18F-FDG and 18F-FLT, positron emitting 
nuclides can be incorporated into a variety of small biologically active molecules 
to image their activity in tissues of interest.  Further, nuclides can be incorporated 
into larger structures, such as nanoparticles, to determine their delivery to tissues 
such as solid tumors (17, 18).  Importantly, the amount of tracer required for PET 
imaging is normally too small to disrupt the kinetics of endogenous molecules, 
ensuring that the tracer will not alter biochemical pathways and confound scans 
(19).   
PET can measure specific processes of tumors for the purpose of 
classification, predicting treatment success, and monitoring tumor response to 
therapy over time.  Tracers for PET are often able to detect or probe for  subtle 
changes in tumor metabolism or intratumoral biochemistry.  PET scans offer the 
opportunity to measure metabolic changes which occur in response to therapy (20-
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22).  For example, 18F-FDG has been studied in the clinic as a prognostic marker 
for progression free survival and overall survival prior to treatment with antivascular 
agents in patients with metastatic renal cell carcinoma (23).  18F-FDG was similarly 
able to predict overall survival and metastasis-free survival in early hepatocellular 
carcinoma prior to surgery (24).  In studies with 18F-FLT, researchers have been 
able to assess early responses to sunitinib treatment in patients with metastatic 
renal cell carcinoma (25).  18F-FLT imaging has also been shown to identify 
progression of pancreatic cancer early into gemcitabine treatment, to potentially 
select patients that may benefit from alternative therapeutic options (26).  
Importantly, different tumors can exhibit varying levels of tracer uptake.  Baseline 
uptake should be considered when choosing tracers to monitor therapeutic 
response in cancers, as one tracer is not likely to be suitable for all cases. 
While identifying tumor location, size, and stage are important aspects of 
imaging in oncology, PET can provide specific information about the biological 
characteristics of an individual tumor.  By designing tracers to measure biological 
pathways of interest, PET can be used to quantitate these tumor characteristics in 
ways which impact therapeutic decisions.  Measuring early changes in tumor 
metabolism and behavior which result from treatment can provide individualized 
information about a patient’s likelihood of response (11, 27, 28).  The ability to 
identify responders early into treatment would allow physicians to make the best 
therapeutic decisions for cancer patients.  Imaging with PET is an invaluable tool 
for the personalization of medicine for solid tumors. 
 
5 
 
 
 
2.  PET for Early Detection of Therapeutic Effects on Solid Tumors 
 In clinical oncology, one of the most promising aspects of PET research is 
the potential to image early tumor response to therapy.  Although new therapies 
for a multitude of cancers are being developed each year, measurable response 
to cancer treatments are extremely heterogenous in patient populations (29-31).  
Traditionally, patients and their physicians were forced to wait until months of 
treatment are completed to determine the extent, if any, of therapeutic efficacy.  
Thus, a means by which physicians could predict therapeutic success or failure 
early into cancer treatments could save patients valuable time, resources, and 
avoid unnecessary side effects. 
 The principle of measuring early metabolic consequences of successful 
therapy has been demonstrated using 18F-FDG imaging.  Multiple studies have 
been performed to evaluate 18F-FDG PET in measuring early response to breast 
cancer treatment, including one of the first of such studies in patients published by 
Wahl et al. (32).  Patients were scanned with 18F-FDG before beginning the first 
cycle of chemotherapy, and at multiple time points throughout therapy.  
Interestingly, significant reductions in 18F-FDG uptake were observed in as little as 
8 days, and continued through day 60 of treatment in women who responded to 
therapy.  Conversely, little change was observed in PET of women who were later 
identified as non-responders.  In another example, by Buvat et al., aimed to identify 
PET measurement thresholds of early therapeutic response in metastatic 
colorectal cancer patients receiving chemotherapy (33).  The authors found that 
after 14 days of therapy, standardized uptake values (SUV) of tumors with 18F-
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FDG PET were able to predict response when compared to pre-treatment scans.  
In thymic epithelial tumors, Segreto et al. measured 18F-FDG uptake in tumors 
before and after three cycles of chemotherapy (34).  Similarly, the authors found 
that changes in 18F-FDG uptake following partial therapy differed between 
responders and non-responders.  In each of these studies, the authors noted that 
early changes in 18F-FDG uptake preceded any measurable changes in tumor 
morphology.  In this way, 18F-FDG PET has demonstrated the utility of measuring 
metabolic changes to assess early therapeutic effects in cancer and results with a 
number of tumor types and treatments have been explored (35-37). 
Although 18F-FDG is among the most commonly used tracers utilized for 
PET, multiple forms of radiolabeled small molecules and macromolecules are 
currently being studied as tracers to image early response to therapy.  With the 
increasing interest in precision personalized medicine, tracers are being 
developed as companions to therapy in order to offer insight into unique behavior 
of a patient’s disease.  One strategy revolves around developing tracers which 
mimic a targeted therapeutic agent in order to assess availability of the target or 
successful delivery of the treatment (38, 39).  Another approach is the design of 
tracers to measure downstream or biologically-related processes in order to 
measure the effect of a treatment (40, 41).  In each case, although the effects of 
the therapeutic strategies may face heterogeneous response in patient 
populations, companion imaging offers a means by which clinicians and 
researchers can more efficiently plan and assess successful treatments for 
patients on an individual basis. 
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3.  Imaging of Nanoparticle Distribution to Assess Treatments that Alter 
Delivery 
 As interest in nanoparticles (NP) for delivery of therapeutic agents to solid 
tumors grows, methods to measure or predict their utility are critically needed.  
Imaging NP can streamline the development and implementation of NP 
treatments, and can serve as tools for personalized medicine.  NP platforms for 
drug delivery  are used to enhance drug deposition in tumor tissues to increase 
effective therapeutic doses (42).  However, preclinical successes in treating tumors 
with NP are often met with failure in human trials due to ineffective delivery to 
tumors in the heterogeneous patient population (43, 44). 
By providing non-invasive, quantitative measures of NP localization, 
imaging can provide invaluable information of NP distribution in tumors.  With 
imaging, the delivery of NP can be assessed in a patient or lesion, predict 
therapeutic efficacy of NP treatments, and monitor distribution over time or as a 
response to treatment.  While ineffectual NP delivery in human tumors has 
hampered the path to the clinic, researchers are now considering the use of 
therapies which alter the tumor and its microenvironment to improve NP delivery 
(45).  The use of imaging to quantify NP delivery could identify and characterize 
novel methods for improving NP localization to solid tumors.  In the clinic, these 
same NP-based imaging tools can be used to personalize treatments by predicting 
therapeutic outcomes, identifying barriers to delivery, and monitoring changes in 
delivery throughout the course of treatment. 
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“Nanotheranostics” to visualize delivery with non-invasive imaging 
  In addition to delivering therapeutic payloads, many NP can be designed or 
modified for imaging to act as a tracer or contrast agent. Imaging with NP 
(diagnostic NP; Dx-NP) that mimic the systemic distribution of drug-loaded NP 
(therapeutic NP; Tx-NP) can assess the tumor-targeting capacity of the NP 
platform. 
Recently, coupling of targeted therapies with complimentary diagnostic 
imaging has been termed “theranostics” (46).  From this, the emerging field of 
“nanotheranostics” provides tools to measure NP delivery which may predict 
efficacy of NP therapy on an individual basis (47, 48). Examples of a variety of NP 
for imaging are outlined in Table 1.  While imaging with Dx-NP to predict 
therapeutic response has been the goal of nanotheranostics, the potential utilities 
of imaging in NP research are myriad.  Dx-NP can measure the release of 
payloads, or assess drug availability (49).  Non-invasive scans can be repeated 
over time to monitor delivery through the course of treatment. Perhaps the newest 
and least explored utility for nanotheranostics is in evaluating strategies to improve 
NP deposition in tumors with therapies that have an impact on enhanced 
permeability and retention (EPR).  Imaging with Dx-NP can allow researchers and 
clinicians evaluate how therapies such as radiation, chemotherapy, and anti-
vascular agents affect the delivery of NP.  Utilizing imaging with NP could 
streamline NP development, identify the best combination therapies and treatment 
timelines, and narrow the gap between preclinical studies and clinical application 
of NP. 
9 
 
 
 
Table 1.  Examples of nanoparticle platforms for imaging 
Platform Name Tumor Model Modality 
Therapeutic 
Component 
Ref. 
Liposome 
 Liposomal Gd-
DTPA 
Colon DCE-MRI None (50) 
 MM-302 HER2+ breast PET Dox; Anti-
HER2 antibody 
fragment 
(51) 
 Fluorescently-
labeled 
liposomes 
Murine colon NiR Imaging None (52) 
 Fluorescent 
PEGylated 
siRNA-
lipoplexes 
Murine colon NiR Imaging siBcl-2 (53) 
 Liposomal 
iodine 
Primary 
sarcoma 
CT None (54) 
 99Tc-liposomes Feline soft 
tissue 
sarcoma 
Gamma 
camera 
None (55) 
 99mTc-DSPE-
PEG2000 
Rat 
fibrosarcoma 
Gamma 
camera 
None (56) 
 99Tc-labeled 
liposomal Dox 
Head and 
neck; 
Squamous cell 
carcinoma 
SPECT Dox (57, 
58) 
      
Copolymers 
 HPMA-Dox Prostate MRI Dox (59) 
 HPMA-
gemcitabine 
Prostate Gamma 
camera 
Gemcitabine (59) 
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Dendrimer 
 G8-Gd-D Squamous cell 
carcinoma 
MRI None (60) 
      
Iron oxide 
nano-
particles 
     
 Ferumoxyol 
(Feraheme) 
Murine 
mammary; 
Pancreas 
MRI None (61, 
62) 
 Angiospark680 Breast NiR Imaging None (63) 
      
Macro-
molecular 
Complexes 
     
 Albumin-
(GdDTPA)30 
Breast DCE-MRI None (64) 
 Gadofosveset 
trisodium 
(albumin bound) 
Mouse 
mammary 
MRI None (61) 
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Enhanced Permeability and Retention 
 NP have long been thought to localize to solid tumors via EPR.  Tumors 
generate aberrant blood vessels which can harbor gap openings of between 400 
and 600 nm (65).  Coupled with poor lymphatic drainage, leaky tumor vasculature 
causes large particles to become trapped in tumor interstitial spaces (66).  NP, 
which are usually 10 to 100 nm, have been shown preclinically to passively 
accumulate in tumors due to EPR, often regardless of targeting surface moieties 
(67, 68).   
 Perhaps the most commonly cited barrier to therapeutic NP efficacy is 
delivery to and penetration of tumor tissues, despite preclinical results (43, 69).  
Researchers have since suggested that EPR is hampered in humans by conditions 
of high interstitial fluid pressures (IFP), increased pericyte coverage, inconsistent 
vessel pore sizes, and thicker collagen and extracellular matrix (ECM) layers (70-
73).  The parameters which define EPR are highly variable in patients, and are 
based on dynamic conditions that change over time. 
 The task of improving NP accumulation in solid tumors can be viewed from 
two perspectives: (1) adjustment of the physical parameters of the NP, and (2) 
therapeutic modulation of the tumor and its microenvironment (74).  Studies of the 
former are already actively utilizing imaging (75, 76).  By adding diagnostic 
components to the NP platform, researchers can measure differences in systemic 
distribution of NP during the design, modification, or fine-tuning of NP.  This can 
mean manipulating size and shape, surface chemistry, targeting moieties, etc. 
(77). 
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The latter describes the use of therapeutic interventions which make tumor 
tissues more available to NP infiltration.  Many currently-accessible treatments 
have the capacity to influence EPR parameters (78).  To improve NP delivery, 
multiple groups are utilizing therapies that affect tumor blood flow, vascular 
permeability, IFP, and ECM components (79, 80).  The goal is to reduce or remodel 
the physical barriers to macromolecular profusion in human tumors, and provide 
therapeutic avenues to improve outcomes of NP which are already in or near 
clinical trials.  Nanotheranostics studies utilize various imaging modalities to 
measure and monitor differences in NP distribution patterns which result from 
additional therapies/interventions.  A summary of these studies is provided in Table 
2. These studies identify tools and techniques for personalization of NP therapies 
for cancer. 
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Table 2.  Preclinical studies of Imaging NPs for measuring therapeutically-altered NP delivery 
Therapeutic 
Strategy 
Treatment Drug 
NP Imaging 
Probe 
Modality Observed Effect Ref 
Targeting 
Tumor 
Vasculature 
      
 VEGFR 
inhibition 
Axitinib Albumin-
(GdDTPA)30 
DCE-MRI Reduced vascular 
permeability of NP 
(64) 
 Alk5 
inhibition 
LY-364947 Ferumoxytol 
(Feraheme) 
MRI Modest improvement of 
enhancement 
throughout tumor 
(61) 
  A-83-01 Liposomal Gd-
DTPA 
DCE-MRI Increased AUC of Gd 
accumulation in tumor 
(50) 
Tumor 
Debulking 
      
 Cytotoxic 
Therapy 
Cyclo-
phosphamide 
64Cu-MM-302 
(HER2-targeted 
liposomal Dox) 
PET Reduced IFP; 
increased liposomal 
delivery to tumors; 
improved Tx efficacy 
(51) 
  S-1 (Tegafur) Fluorescent 
PEGylated 
liposomes 
NiR 
Imaging 
Increased liposomal 
delivery; increased 
homogeneity 
(52) 
   Fluorescent 
siRNA lipoplexes 
NiR 
Imaging 
Increased uptake of 
lipoplexes in tumors; 
improved therapeutic 
efficacy 
(53) 
 
 
Radiation       
 Single 
High-Dose 
RT 
N/A G8-Gd-D MRI Increased 
enhancement at 
multiple time points 
(60) 
   Liposomal Iodine Dual-
energy CT 
Increased iodine 
concentrations in 
tumors; increased 
permeability 
(54) 
   HPMA-Dox (Gd) MRI Enhanced tumor 
localization; increased 
efficacy and toxicity 
(59) 
   HPMA-
gemcitabine (131I) 
Gamma 
Camera 
Enhanced tumor 
localization; increased 
efficacy, modest 
toxicity 
(59) 
   Angiospark680 NiR 
Imaging 
Increased 
accumulation of probe 
in tumors; increased 
efficacy of subsequent 
Doxil Tx 
(63) 
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Thermal 
Ablation 
      
 Microwave 
Ablation 
N/A 99Tc-Liposomes Gamma 
Camera 
Increased liposome 
accumulation in tumor 
(55) 
 Warm 
Water 
Catheter 
N/A 99mTc-DSPE-
PEG2000 
Gamma 
Camera 
Increased liposome 
accumulation in tumor; 
increased Dox delivery 
with subsequent Doxil 
Tx 
(56) 
 Radio-
frequency 
thermal 
ablation 
N/A 99Tc-Liposomal 
Dox 
Gamma 
Camera; 
SPECT 
Increased liposome 
delivery to tumor; 
increased levels of Dox 
in resected tumor 
tissues 
(57) 
Targeting 
ECM and 
BM 
      
 Collagen 
remodeling 
Collagenase-2 99Tc-Doxil SPECT Transient drop in IFP; 
increased intratumoral 
Doxil localization 
(58) 
  Losartin Ferumoxytol MRI Increased tumor blood 
pool as measured with 
ferumoxytol; enhanced 
uptake of subsequent 
SMI drugs 
(62) 
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Changes in NP Delivery Due after Therapeutically Targeting Tumor Vasculature 
Large pores and gaps in tumor vessel walls allow for extravasation of 
macromolecules in circulation, including NP (81).  These characteristics are 
heterogeneous in clinical populations, making them a somewhat difficult target for 
cancer therapies (82).  Although often lacking widespread impact as 
monotherapies, drugs which target angiogenesis or vessel integrity have been 
shown to improve outcomes when combined with chemotherapy (83, 84).  One 
example is bevacizumab (AvastinTM; Genentech, San Francisco, CA), a vascular 
endothelial growth factor (VEGF)-targeted antibody which is FDA approved in 
combination with chemotherapy in multiple tumor types (85).  Another example is 
ziv-aflibercept injection (Zaltrap®, Sanofi and Regeneron Pharmaceuticals, Inc., 
Tarrytown, NY), which is a recombinant fusion protein which contains domains 
which bind to portions of VEGF, and has been FDA approved for combination with 
chemotherapy in colon cancer (86).  However, the ability to modulate tumor 
vasculature properties is an attractive concept when facing the problem of 
inconsistent NP distribution in tumors.  Thus, agents which target a number of 
vascular properties have been suggested as a means of altering EPR to enhance 
NP delivery. 
3.1.  Imaging the Effects of Targeting Tumor Angiogenesis on NP Deposition 
in Solid Tumors 
Anti-angiogenic therapies like bevacizumab are designed to disrupt tumor 
blood vessel formation and ultimately starve tumors of nutrients.  These drugs 
have led to modest improvements in clinical outcomes when combined with 
conventional chemotherapy (83, 84). 
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3.1.1.  Anti-VEGF therapies 
While depletion of blood vessels is the intended outcome of anti-angiogenic 
therapy, there is some evidence that these drugs cause temporary remodeling or 
“normalization” of blood vessels, which may affect drug delivery for a short time 
(87, 88).  With the expanding use of anti-angiogenic therapies in the clinic, a 
complete understanding of their effect on NP delivery will be important as N5P 
enter clinical trials, and treatment regimens. 
A study performed by Wilmes et al. measured the effect of blocking VEGF 
signaling on perfusion of small and large contrast agents with DCE-MRI in BT474 
breast tumor xenografts in mice (64).  The group utilized a novel small molecule 
inhibitor of VEGF receptor tyrosine kinase, axitinib (AG-013736; Inlyta; Pfizer, 
NY, NY) to disrupt tumor vessel properties and growth.  Administration of the drug 
for three weeks showed dramatic antitumor action.  DCE-MRI images to measure 
early drug effects were obtained with both macromolecular albumin-bound 
gadolinium-bound diethylenetriaminepentaacetic acid (GdDTPA) and low 
molecular weight GdDTPA contrast agents before and after axitinib therapy. 
After only seven days of axitinib administration, the authors noted a marked 
decrease in tumor perfusion compared to control tumors.  Reduced vessel 
permeability was evident from significant drops in tumor endothelial transfer 
coefficients (Kps) calculated for both contrast agents.  Histology staining for CD31 
performed in resected tumor tissues showed a reduced number of microvessels 
after seven days of treatment, which complements the imaging data.  The 
measurable decrease in albumin-bound GdDTPA perfusion into tumor tissues 
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following short-term axitinib therapy suggests that imaging with DCE-MRI can 
provide early and dynamic measures of changes in macromolecular distribution.  
This study indicates that macromolecular delivery to tumors can be dramatically 
altered by therapeutic intervention, and provides rationale for utilizing imaging to 
measure these effects early into treatment. 
3.1.2.  Targeting TGF-β 
Multiple studies have demonstrated that NP accumulation in solid tumors 
can be enhanced by treatment with agents which cause tumor vessels to become 
leaky (89, 90).  A popular target is the transforming growth factor (TGF)-β pathway, 
since blocking the kinase activity of the TGF-β1 receptor has been shown to 
increase tumor vessel leakage (91).  Drugs that inhibit TGF-βR1, also known as 
activin-like kinase 5 (Alk5), are widely available and relatively well characterized, 
which simplifies their incorporation into nanotheranostic studies. 
Daldrup-Link et al. chose to utilize MR imaging to measure the effect of 
Alk5-inhibitor [3-(pyridine-2-yl)-4-(4-quinonyl)]-1H-pyrazole (LY-364947 
Calbiochem, San Diego, CA) on the delivery of NP-based contrast agents in 
transgenic mouse mammary tumor virus-driven expression of the polyoma middle 
T oncogene (MMTV-PyMT) adenocarcinoma, as well as an orthotopic 
glioblastoma model (61).  MRI images were performed with gadofosveset 
trisodium (Ablavar), a small molecule contrast agent which binds albumin to form 
macromolecular complexes in circulation, as well as ferumoxytol (Feraheme), an 
iron oxide NP.  Images were obtained at baseline, and following 6 days of 
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treatment with LY-364947, i.p. every other day to visualize the effect of Alk5 
inhibition on NP delivery. 
In tumors subjected to Alk5 inhibition, tumor enhancement increased 
threefold compared to controls in MR images with gadofosveset, primarily in the 
tumor periphery, and twofold in images with ferumoxytol, throughout tumor tissues. 
The authors suggest that Alk5 inhibition may be able to improve NP delivery and 
efficacy, and that this effect can be visualized with NP contrast agents for MR 
imaging.  In this way, image-guided modulation of TGF-β signaling can be used to 
personalize NP therapies. 
Another study, carried out by Minowa et al. in mice bearing colon 26 tumors, 
measured the effect of Alk5 inhibition with A-83-01 on NP delivery by performing 
DCE-MRI with liposomal Gd-DTPA.  The authors compared baseline scans to 
scans acquired 24 hours after initiating treatment, which consisted of two injections 
of A-83-01.  Compared to baseline scans, treatment resulted in a 3.8-fold increase 
in the AUC of Gd concentration (Figure 1).  This implies that even short-term Alk5 
inhibition can markedly improve liposome delivery to the tumor. Importantly, 
imaging with a liposomal contrast agent for MRI was able to identify improved 
liposomal delivery very early into Alk5 inhibition with A-83-01. 
 
4.  PET with Radiolabeled Pyrimidine Analogs for Early Assessment of Drug 
Efficacy in Tumors 
Just as oncologists have relied on tissue biopsies to help define and stage 
tumors, PET images can be used to quantitatively assess the metabolic behavior 
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of tumors.  However, while biopsies involve invasive procedures and produce a 
limited sample, PET images non-invasively provide information about the entire 
tumor and surrounding tissues.  In this way, PET is ideal for longitudinal studies of 
tumor metabolism and for measuring changes in response to therapy (92, 93).  
While response to treatment is usually confirmed by morphological changes in 
tumor tissues (e.g. tumor size, tissue necrosis, etc.) (94), PET can measure 
biochemical shifts indicative of therapeutic response prior to any noticeable 
changes in tumor morphology. 
PET Imaging of Cellular Proliferation 
 Although many studies have demonstrated the usefulness of 18F-FDG PET 
in evaluating cancer treatment response, FDG imaging has limitations (95).  As a 
radiolabeled form of glucose, 18F-FDG is capable of measuring changes in glucose 
metabolism that result from treatment.  Tumor cells often exhibit a highly glycolytic 
metabolism, whereby glucose is converted to lactate for ATP synthesis.  This 
occurs in lieu of ATP generation through oxidative phosphorylation (96).  Increased 
glucose consumption is one of the primary reasons that 18F-FDG is expected to be 
taken up in greater amounts by tumor tissues (97).  However, there is evidence 
that 18F-FDG uptake is not ubiquitous in all tumors, and can be affected by a variety 
of different tumor- or microenvironment-specific mechanisms (98-100).  In fact, 
18F-FDG uptake in tumors, while still an important tool for clinicians, may not 
provide the most direct measure of tumor response to therapy.  Thus, other tracers 
developed for PET may provide a more straightforward measure of early 
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therapeutic response in tumors by measuring processes which are directly related 
to tumor survival and progression. 
 
Pyrimidine Analogues 
 One of the fundamental traits of a tumor is the ability to maintain and 
increase proliferative behavior (101).  Cells in proliferative tissues must duplicate 
their DNA to divide, a process requiring availability of purines and pyrimidines.  
Cellular consumption of thymidine is favored for measuring DNA synthesis and cell 
division.  Compared to other nucleosides, thymidine is only incorporated in nuclear 
DNA, and not utilized in forming RNA (102).  Exogenous uptake of natural 
thymidine in cells correlates with S phase of the cell cycle.  To exploit the direct 
relationship between cellular thymidine salvage and cellular division for tumor 
imaging, multiple radiolabeled thymidine analogues have been developed for PET 
(103). 
 Of the thymidine analogues for oncological PET, 3'-[18F]fluoro-3'-
deoxythymidine (18F-FLT) is the most widely accepted and utilized (104, 105).  The 
replacement of the 3’ hydroxyl group on a thymidine molecule with 18F allows the 
tracer to be taken up into cells and phosphorylated, but not incorporated into 
growing DNA without inducing termination (106).  18F-FLT is phosphorylated by 
thymidine kinase 1 (TK1), which traps it within cells following incorporation (15).  
18F-FLT has been suggested as a marker of proliferation in tumors by measuring 
TK1 activity during its metabolism via the thymidine salvage pathway (107). Tracer 
uptake correlates with immunohistochemical staining for proliferation marker Ki-67 
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in subsequently resected tissues (108). Clinically, 18F-FLT PET is used to 
approximate tumor proliferation, offering insight into the aggressiveness of a tumor 
and its capacity to progress. 
 Although less commonly studied than 18F-FLT, other thymidine analogues 
have been developed as PET tracers.  These include, but are not limited to FMAU 
(1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine), FIAU (2'-fluoro-2'-deoxy-
1-beta-D-arabinofuranosyl-5-iodo-uracil), and FAU (1-(2′-deoxy-2′-fluoro-β-d-
arabinofuranosyl) uracil) (103).  Of these, 18F-FMAU has been of interest for 
imaging proliferation in tumors as an alternative to 18F-FLT.  The fluorine group on 
18F-FMAU is attached at the 2’ position of thymidine, leaving the 3’ hydroxyl group 
intact for 18F-FMAU incorporation into DNA (109).  An advantage of 18F-FMAU over 
18F-FLT for PET is that 18F-FMAU does not demonstrate the same high uptake in 
tissues like bone marrow, making identification of tumors in these tissues more 
feasible (110).  One limitation of both FLT and FMAU is high uptake in the liver of 
humans, which is due to metabolism rather than proliferation (111, 112)(refs).  This 
is likely due to the nature of FMAU phosphorylation which, unlike FLT, occurs 
predominantly by thymidine kinase 2 (TK2), not TK1 (102).  Interestingly, TK2 
phosphorylation of thymidine (and its analogues) is associated with the synthesis 
of mitochondrial DNA, not nuclear DNA (113).  While both 18F-FLT and 18F-FMAU 
are taken up by tumor tissues during thymidine salvage, the phosphorylation of 
these by TK1 and TK2 respectively leads to differential retention.  This, in turn, 
requires distinct interpretation of PET scans performed with either tracer. 
FLT and predicting therapeutic response 
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 While studies of the other thymidine analogues remain relatively limited, 
multiple researchers have suggested that the utility of 18F-FLT lies in imaging early 
response to therapy.  Tumor tissues, while normally rapidly dividing, often slow or 
stall proliferative processes when under stress caused by treatment (102).  The 
effects of anticancer drugs, particularly of drugs which target DNA synthesis, have 
been measured early into treatment with 18F-FLT (107). 
In preclinical studies of 18F-FLT PET in lymphoma, Graf et al. found that 18F-
FLT uptake significantly decreased in tumors treated with doxorubicin after only 48 
hours (114).  Similarly, Ullrich et al. found that 18F-FLT uptake in erlotinib-sensitive 
non-small cell lung tumors significantly decreased after two days of therapy 
compared to drug-resistant controls (115).  A clinical study in esophageal 
squamous cell cancer patients, performed by Chen et al., demonstrated that 18F-
FLT scans performed before and 4 weeks into chemotherapy or radiotherapy could 
distinguish between responders and non-responders (116).  It is important to note 
that in these studies 18F-FLT was directly compared to 18F-FDG, and in each case 
18F-FDG did not have the predictive power demonstrated by 18F-FLT.  The growing 
base of evidence supporting the use of 18F-FLT in predicting response early into 
cancer treatment has strengthened the utility of PET in oncology (117).  Further, 
the variety of other thymidine analogue tracers could lead to new methods for 
measuring the early effect of therapies for a variety of cancers. 
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CHAPTER 2.  LIPOSOMAL 64CU-PET IMAGING OF ANTI-VEGF DRUG 
EFFECTS ON LIPOSOMAL DELIVERY TO COLON CANCER XENOGRAFTS. 
1.  Introduction 
 Globally, colorectal cancer (CRC) is the third most common cancer in men 
(approximately 746,000 cases) and the second most common in women 
(approximately 614,000 cases) as of 2012 (118, 119).  The push for precision 
medicine has led to a greater understanding of the molecular and genetic subtypes 
of CRC among the population (120-123), and promoted the search for prognostic 
and predictive biomarkers.  However, while multiple molecular markers have 
shown promise as prognostic indicators (124, 125), attempts to utilize them in the 
clinic have led to conflicting results (126-129).  Thus, tumor stage and supporting 
histological analysis remain the primary basis for therapeutic decision making in 
CRC (130, 131). 
 In addition to the search for prognostic markers for CRCs, research has also 
focused on uncovering better drug options.  Standard cytotoxic agents for CRC 
include 5-fluorouricil (5FU), often combined with irinotecan and/or oxaliplatin (131-
139).  In patients with advanced disease almost all patients still develop resistance 
to treatment and succumb to tumor growth (140, 141).  Targeted antibodies are 
regularly used in treating mCRC, including agents which target vascular 
endothelial growth factor (VEGF) and its receptor (VEGFR) (142).  Targeting of 
VEGF pathways in CRC is designed to reduce tumor blood supply by disrupting 
tumor vessels, and has had some success in the clinic (143, 144).  One such 
therapy is bevacizumab (bev; Avastin™; Genentech, San Francisco, CA), a VEGF-
targeted monoclonal antibody, has been approved for CRC patients in combination 
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with various chemotherapy regimens.  Unfortunately, most therapeutic options in 
CRC have faced the problem of resistance in the clinic, often due to the 
heterogeneous nature of colon tumors (144-148).   
 Recently, there has been a growing interest in the development of 
nanoparticle-based therapies, such as liposomes (LP), for cancer as multiple 
preclinical studies have shown notable success in cellular and animal models (149-
155).  Clinical trials utilizing LP for CRC treatment focus primarily on delivery of 
well-characterized drugs, including irinotecan and its metabolite, SN-38, or 
doxorubicin (130, 156, 157). LP deposition in solid tumors is heavily influenced by 
enhanced permeability and retention (EPR), making the state of tumor blood 
vessels a key factor in delivery.  Theranostic approaches for imaging delivery of 
LP could provide vital insight into the probability of success when treating with LP 
platforms for drug delivery (158-160).  In this study, we have utilized a 64Cu-loadable 
liposome formulation to image the effects of short-term bev treatment on LP 
delivery to colon tumor xenografts in mice.  We chose to target tumor vasculature, 
as the state of vessels in solid tumors is critical in defining EPR, and thus 
macromolecular delivery (161-163).  Although the long-term effects of bev on tumor 
vasculature have been established, there is evidence that bev begins altering 
tumor vessels and affecting vascular permeability early into treatment (164).  Thus, 
we aimed to measure any early changes in LP localization induced by short-term 
bev with PET, and monitor subsequent therapy with liposomal irinotecan (LP-I; 
MM-398; Onivyde®; Merrimack Pharmaceuticals Inc., Cambridge MA).  In doing 
so, we generated a system to measure dynamic changes in LP deposition which 
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could affect the efficacy of LP-based therapies on an individual basis.  
Furthermore, we were able to non-invasively measure significant differences in LP 
delivery between bev-treated tumors and control tumors early into bev treatment.  
Finally, the results seen with PET correlated with subsequent monitoring of 
treatment efficacies, suggesting that this platform could have utility in predicting 
and monitoring therapeutic LP success. 
2.  Materials and Methods 
Materials 
 HT-29 cells and McCoy’s 5a Modified Medium were purchased from ATCC 
(Manassas, VA) and kept below 15 passages following receipt.  4-DEAP-ATSC 
chelator, empty MM-DX-929 liposomes, and LP-I were provided by Merrimack 
Pharmaceuticals, Inc. (Cambridge, MA). 64CuCl2 was purchased from the 
Department of Radiology at Washington University (St. Louis, MO).  Chelation 
efficiency was measured with iTLC-SG plates (Agilent Technologies, Santa Clara, 
CA).  Loading efficiency was assessed with Sephadex G-50 DNA Grade Illustra 
Nick columns (GE Healthcare, Pittsburg, PA). 
 Gamma spectroscopy was performed on a Packard Cobra II gamma 
counter (Perkin-Elmer Inc., Waltham, MA).  PET scans were acquired on an R4 
microPET (Concorde Microsystems, Knoxville, TN).  CT images were acquired 
using an Inveon microSPECT/CT (Siemens Preclinical Imaging Solutions, 
Malvern, PA).  Images were registered and analyzed using PMOD Image Matching 
and Fusion Tool ver3.6 (PMOD group, Switzerland).  Statistical analyses were 
performed using GraphPad Prism, ver7 (GraphPad Software Inc., La Jolla, CA). 
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Labeling MM-DX-929 with chelated 64Cu 
 Upon receipt of 64CuCl2, 64Cu was chelated with 4-DEAP-ATSC (98±2% 
chelation efficiency), followed by loading into empty liposome (95±3% loading 
efficiency).  Briefly, 64CuCl2 was vortexed with 4-DEAP-ATSC solution (0.06 mg/ml 
chelator in 0.1M citrate buffer, pH 6) at room temperature for 10 seconds, then 
allowed to sit for one minute and vortexed again.  Efficiency of 64Cu chelation was 
determined by diluting a sample in citrate buffer for instant thin layer 
chromatography as described previously (165).  Briefly, the radioactivity at the 
solvent front (free 64Cu in solution) and at the sample origin (64Cu-DEAP-ATSC 
complex) was measured by gamma spectroscopy of the iTLC plates.  Greater than 
90% chelation efficiency was required to proceed to loading. 
 64Cu-MM-DX-929 was prepared by mixing 64Cu-DEAP-ATSC with empty 
MM-DX-929 liposomes (15 mM phospholipid in 10 mM HEPES buffered saline, 
150 mM sodium chloride, pH 6.5) and heated for 10 minutes at 65 °C, followed by 
immediate cooling in an ice water bath for one minute, as previously described 
(165).  Loading efficiency of 64Cu was assessed by performing size exclusion 
chromatography on an Illustra NICK column with a small sample of prepared 64Cu-
MM-DX-929 in HEPES buffered saline (HBS). Radioactivity of the eluent 
containing labeled 64Cu-MM-DX-929 in HBS, and the column containing 64Cu-
DEAP-ATSC was measured with gamma scintigraphy.  Greater than 90% labeling 
efficiency was achieved before proceeding with animal imaging. 
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Cell Culture 
 HT-29 human colorectal adenocarcinoma cells were cultured in McCoy’s 5a 
Modified Medium supplemented with 5% fetal bovine serum and 1% 
penicillin/streptomycin, as described by ATCC.  Cells were kept at 37°C with 5% 
CO2 and were passaged with trypsin at approximately 80% confluence.  Prior to 
inoculation in mice, cells were not passaged more than ten times in culture.  Cell 
line identity was authenticated at time of all studies with the PowerPlex 16 
System from Promega (Madison, WI) in the Applied Genomics Technology Center 
at Wayne State University. Analyses were performed using ATCC and DSMZ 
reported karyotypes. Tumor fragments were subcutaneously implanted into SCID 
NCr female mice on day 0 by trochar. 
Animal Studies 
Tumor model: Cultured HT-29 human colorectal adenocarcinoma cells were used 
to establish a subcutaneous tumor model in female SCID NCr mice (Charles River 
Labs; MA) and thereafter maintained in serial passage.   
MicroPET studies: Schematic representation of mouse study design is presented 
in Figure 1.    Tumors were upstaged to 250mg (range: 200-300mg, day 12), and 
mice non-selectively randomized into their respective control (No Rx) and 
treatment groups (bev). All mice were imaged with microPET before and after bev 
treatment (on days 13 and 20) 24hr after intravenous (IV) administration of 64CuCl2 
MM-DX-929. Scans were compared for changes in LP accumulation during this 
time period.  Mice were euthanized under anesthesia with whole blood and tissues 
collected after the second PET for biodistribution measurements and histological 
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analysis.   For subsequent studies, after the 2nd scan, mice were further divided 
into 4 groups of n=6 (No Rx, Bev, LP-I, and Bev + LP-I) to assess tumor 
progression post bev treatment, with or without LP-I, compared to untreated 
controls.  All mice were weighed and observed daily for the duration of the study. 
Tumors were measured by caliper 2-3x/weekly with the formula [volume (mg) = 
length (mm) x width2 (mm2)/2] used to calculate tumor mass.   
Tracer preparation and injection: Empty LP MM-DX-929 (Merrimack 
Pharmaceuticals, Cambridge, MA) were labeled with 64CuCl2 chelated with 4-
DEAP-ATSC).  Mice were administered 200-300 µCi/injection, IV within a 0.1 to 
0.3 ml volume range; 22-24 hours prior to each microPET scan.  
Drug preparation: Bevacizumab was prepped fresh for each injection from 25 
mg/ml stock diluted with 0.9% sterile saline, pH 6.0 and injected intraperitoneally 
(IP) at 5 mg/kg in a volume of 0.2ml/20g mouse on days 14 and 17 (2q7d). 
Liposomal Irinotecan (LP-I; MM-398; Onivyde®, Merrimack, Cambridge, MA) was 
prepped fresh for each injection from 5.05mg/ml stock diluted with 0.9% sterile 
saline, pH 6.0 and injected IV at 10 mg/kg in a volume of 0.2 ml/20g mouse on 
days 21, 24, and 28.  
All animal studies were approved by and performed in strict accordance with the 
policies of the Institutional Animal Care and Use Committee (IACUC) at Wayne 
State University.  
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Figure 1.  Liposome animal study design.  Schematic representation of 
treatment groups and timeline for mice treated with bev, LP-I, bev followed by LP-
I, and controls. 
 
Animal Imaging with 64Cu-MM-DX-929 PET 
 64Cu-MM-DX-929 (104 nm) was used to approximate the systemic 
distribution of LP-I (110 nm), as it has been shown to predict the accumulation of 
LP-I in solid tumors (166).  Following 64Cu-liposome preparation, mice received 
approximately 200-300 µCi of 64Cu-MM-DX-929 (20 μmol/kg lipid) intravenously 
via the tail vein.  64Cu-MM-DX-929 was imaged with PET 24±2 hours post-injection, 
as liposomes remain in the blood pool for extended periods before depositing in 
tissues.  Anesthesia was induced with 3% inhaled isoflurane, and maintained 
during scanning with 2% isoflurane.  Mice were positioned prone on the scanner 
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bed with heating pad to maintain body temperature.  Fiducial markers labeled with 
64Cu were fixed to the bed for subsequent alignment of PET and CT images. PET 
acquisition was performed for 10 minutes, followed by CT scanning 10 minutes to 
obtain anatomical images. 
 Attenuation correction was performed on the whole body microPET images 
based on previously recorded transmission scans.  Images were reconstructed by 
applying an iterative ordered-subsets expectation maximization 2-dimensional 
algorithm (167).  Together with scatter correction, these parameters yielded an 
isotropic spatial resolution of approximately 2mm in full width at half maximum 
(168).  Prior to study, a phantom for 64Cu was scanned to calculate conversion 
from counts/pixel/minute to kBq(μCi)/cm3. 
PET/CT image registration and analysis 
 PET and CT images were registered and aligned using the PMOD Image 
Matching and Fusion Tool.  Regions of interest (ROIs) were defined manually on 
individual planes of the PET, using the aligned CT images for anatomical 
reference.  3-dimensional volumes of interest (VOIs) were generated from the 
stacked ROIs of the tissue of interest.  Activity in the VOIs, as detected by PET in 
kBq(μCi)/cm3, was converted to standardized uptake values based on injected 
dose and body weight.  SUVmax values were calculated by averaging the max pixel 
value in the ROI of the three hottest consecutive planes in a tissue, and normalizing 
to injected dose and body weight. 
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64Cu-MM-DX-929 PET imaging of short-term bev effects 
 A baseline 64Cu-MM-DX-929 PET was performed on all mice at day 14 post-
tumor implant, followed by half of the mice receiving two injections of bev over 
seven days.  Bev was administered IP at 5 mg/kg in a single injection performed 
on days 14 and 17 (two total injections). All mice received a second 64Cu-MM-DX-
929 PET on day 20.  Day 20 scans (post-treatment) were compared to scans from 
day 13 (baseline) and analyzed for changes in 64Cu-MM-DX-929 delivery to tumor.  
Results were compared between bev-treated and control mice. 
Whole body tissue distribution of 64Cu-MM-DX-929 
 64Cu-MM-DX-929 retention in bulk tissues was assessed by gamma 
spectroscopy of resected tissues.  Briefly, following the second PET scan (day 7), 
mice were sacrificed and tissues harvested (n=8).  These included tumor, liver, 
heart, lung, intestine, stomach, kidney, spleen, and blood.  Tissues were washed 
in water, weighed, and activity was measured for one minute on a gamma counter.  
Activity in tissues was decay corrected to time of injection and normalized to tissue 
weight (kBq/cc).  Tissue biodistribution was compared between bev-treated and 
untreated mice to ensure that bev treatment was not affecting retention of 64Cu-
MM-DX-929 in healthy tissues. 
Immunohistochemistry and microvessel density analysis 
 Tumors resected after the second PET were fixed in formalin and paraffin 
embedded.  Immunohistochemistry for CD34, and staining with hematoxylin 
(Sigma Aldrich, St. Louis, MO) was performed on 5 µm slices, and digital images 
of the entire cross section were captured.  Sample identities were blinded, and 
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images were analyzed with Pannoramic Viewer ver1.15.4 (3DHISTECH Ltd., 
Budapest, Hungary).  For each tissue, five distinct areas of 200 mm2 were utilized 
in assessing microvessel density.  Briefly, tumor blood vessels (as identified by 
CD34 staining) were counted in each section, and distance measurements across 
the widest diameter of each vessel were used to determine vessel size.  The 
average number of vessels per cm3 and the average vessel diameter were 
calculated. 
64Cu-labeled liposome interactions with macrophage populations in blood 
 64Cu-MM-DX-929 as well as 64Cu-MM-302, a structurally related liposome, 
were incubated in human whole blood for one hour with gentle rocking at 37˚C.  
Incubated blood samples, as well as samples collected from clinical trials of 
patients scanned with 64Cu-MM-302, were subjected to density gradient 
centrifugation over a Ficoll-Hypaque gradient.  Plasma, white blood cells, and red 
blood cells (RBCs) were separated via multiple centrifugation steps.  White blood 
cell fractions were incubated in cell culture flasks with lymphocyte-cultured medium 
for 3 hours to induce macrophage adherence.  Non-adhered lymphocytes were 
carefully aspirated, and attached monocytes were collected via Trypsin wash.  
Plasma, RBC, lymphocyte, and macrophage fractions were measured with gamma 
scintigraphy to determine 64Cu-LP content.  Values are represented as %total 
counts. 
 Whole blood from patients receiving 64Cu-MM-302 was also subjected to 
size exclusion chromatography to determine LP stability at multiple time points, 
including 1 hour, 24 hours, and 48 hours after injection. 
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Statistical Analysis 
 Tumor growth curves with mean ± standard error was plotted and growth 
rates were tested with linear mixed model.  Tumor latency to 1 gram total burden 
was tested with Kruskal-Wallis test, after normality assumption was evaluated with 
Shapiro-Wilk test. Statistical analyses were performed using R version 3.2 (The R 
Foundation for Statistical Computing). All other statistical analyses were performed 
using GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA).  Data were 
presented as the mean ± standard error.  Comparisons between the bevacizumab 
and control were performed using two-sample Student’s t-test. A p-value of <0.05 
was considered statistically significant. 
3.  Results 
3.1.  64Cu-MM-DX-929 PET can detect significant differences in LP delivery   
between colon tumors treated with bev and untreated controls 
 Liposome distribution in mice bearing subcutaneous HT-29 colon tumor 
xenografts was measured with 64Cu-MM-DX-929 PET at baseline prior to any 
treatment. Due to the extended circulation times of liposomes in the body, images 
were acquired 24 ± 2 hours following tracer injection (approximately two half-lives 
of 64Cu, t1/2 = 12.7 hours) to allow extravasation from the blood pool (165).  Tracer 
uptake was notable in liver (due to extensive vasculature) and spleen, and was still 
visible in the heart (residual blood pool).  Tumors were easily detectable with 64Cu-
MM-DX-929 PET, with relatively ubiquitous tracer distribution at baseline.  
 By measuring changes in tumor SUVmax between baseline and post-
treatment scans (%ΔSUVmax) we found the difference in %ΔSUVmax of bev-treated 
tumors compared the controls to be statistically significant, p=0.0002 (Figure 2).  
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This trend was seen when comparing mice (data analyzed as an averaged value 
of both tumors per mouse), but was also true when comparing individual tumors 
(Figure 3).  Scans from two control mice were determined to be un-evaluable due 
to technical issues with one or both PET images for those mice. Changes in 64Cu-
MM-DX-929 PET from baseline to post-treatment were noticeably different 
between tumors treated with bev and untreated controls.  Tumors in control mice 
showed increased 64Cu-MM-DX-929 retention after seven days compared to 
baseline images (Figure 4).  Although these tumors often continued to grow 
between baseline and subsequent scans, increases in 64Cu-MM-DX-929 tumor 
accumulation was independent of individual tumor size or growth rate (data not 
shown).  In mice treated with bev, however, 64Cu-MM-DX-929 delivery to tumor 
tissues appeared to remain stable between baseline and post-treatment scans 
(Figure 5).  Again, these trends were independent of tumor size or growth rate 
(data not shown). 
 
 
 
35 
 
 
 
 
Figure 2.  Changes in SUVmax of HT-29 colon tumors decreased after 
treatment with bev compared to untreated tumors. %ΔSUVmax of liposome 
accumulation in tumor tissues of mice which received no treatment (n=10), 
compared to mice treated with two doses of bev (n=12) as measured by 64Cu-MM-
DX-929 PET. %ΔSUVmax values represent the average %ΔSUVmax of both tumors 
within an individual mouse. (***p=0.0002) 
 
 
Figure 3. SUVmax of individual tumors decreased after treatment with bev 
compared to untreated tumors. Change in SUVmax values measured in individual 
HT-29 tumor xenografts after two injections of bev compared to untreated tumors. 
(p=0.0003) 
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Figure 4.  64Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts 
increases after 7 days without therapeutic intervention.  64Cu-MM-DX-929 
scans of a mouse bearing two subcutaneous HT-29 colon xenografts (outlined) at 
baseline (A) and after seven days with no treatment (B).  Images are coronal slices 
of the mouse midsection with fused PET/CT, PET alone, and CT alone.  PET 
images were scaled from ½ background (kBq/cc) to liver average (kBq/cc) 
calculated based on average values from both scans. 
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Figure 5.  64Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts does 
not increase when treated with two doses of bevacizumab.  64Cu-MM-DX-929 
scans of a mouse bearing two subcutaneous HT-29 colon xenografts (outlined) at 
baseline (A) and after seven days of bev treatment (B).  Images are coronal slices 
of the mouse midsection with fused PET/CT, PET alone, and CT alone.  PET 
images were scaled from ½ background (kBq/cc) to liver average (kBq/cc) 
calculated based on average values from both scans. 
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 Interestingly, 64Cu-MM-DX-929 PET scans visualized more frequent and 
dramatic shifts in the volumetric distribution of tracer across the mass of tumors 
treated with bev.  This suggests that early into treatment, prior to measurable 
morphological differences, 64Cu-MM-DX-929 PET identified altered tumor 
vascularity in bev-treated tumors, as well as early effects of bev on LP distribution. 
64Cu-MM-DX-929 PET images suggest that the early effects of bev may 
substantially alter or limit LP penetration into tumor tissues.  Additionally, changes 
in tracer deposition in individual tumors were more highly variable in bev-treated 
tumors, while control tumors often exhibited similar increases in uptake over time 
(Figure 6).  Taken together, 64Cu-MM-DX-929 PET was able to detect increased 
LP accumulation/delivery in colon tumor xenografts tended to increase as tumors 
progressed without intervention, but this trend was reduced or abolished with only 
two doses of bev.  Thus, with 64Cu-MM-DX-929 PET we were able to measure the 
effects of bev therapy on LP delivery to solid tumors early into treatment. 
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Figure 6.  Changes in HT-29 tumor SUVmax values measured with 64Cu-MM-
DX-929 PET.  Lines represent SUVmax values for individual tumors in mice treated 
with bev (A) or tumors in untreated mice (B). 
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3.2.  Bevacizumab does not alter systemic distribution of 64Cu-MM-DX-929 in 
non-tumor tissues 
 Any treatment with the potential to alter systemic distribution of a PET tracer 
could confound image analysis and uptake quantitation.  To verify that bev did not 
significantly alter 64Cu-MM-DX-929 global uptake in tissues, activity in normal 
tissues (resected immediately following the second PET of selected mice) was 
measure by gamma spectroscopy and compared between treated and untreated 
mice.  No significant differences were detected between normal tissues of bev-
treated mice and control mice (Figure 7).  This demonstrates that systemic 
distribution was not altered in a way which would be confounding for image 
analysis in tissues of interest. 
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Figure 7. Bev treatment did not change overall biodistribution of 64Cu-MM-
DX-929.  %injected radioactive dose per gram of resected tissues was measured 
directly after the second 64Cu-MM-DX-929 PET scan. 
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3.3.  Colon tumor growth was delayed by short-term bev alone, liposomal 
irinotecan alone, or short-term bev followed by liposomal irinotecan 
 Following the second 64Cu-MM-DX-929 PET, bev-treated mice and 
untreated mice were further randomized into the following subsets: (1) untreated 
controls (n=6); (2) short-term bev (2q7d) only (n=6); (3) LP-I only (n=6); (4) short-
term bev followed by LP-I (n=6) (Figure 1).  One mouse assigned to receive LP-I 
only (group 3) was not included in data assessments due to lack of drug availability 
at the time of study.  Mice were treated and tumor progression was monitored until 
tumor burden or weight loss warranted euthanasia.  Tumor growth was considered 
individually, as well as by per-mouse analysis of total tumor burden. 
 As expected, HT-29 tumors in mice which received no treatment exhibited 
unrestrained growth (Figure 8A).  Treatment with two doses of bev resulted in a 
measurable but modest delay in tumor progression compared to controls.  
Interestingly, tumors in mice treated with LP-I also exhibited delayed growth 
compared to controls, despite being administered later than bev, at advanced 
stage of disease.  Succeeding short-term bev with LP-I demonstrated tumor 
inhibition compared to untreated controls, although there was no notable 
therapeutic advantage to this combination compared to bev or liposomal irinotecan 
alone with the specific doses and regimens tested.   
As was seen in the PET scans with bev, individual tumor and mouse 
responses varied in each of the treatment groups.  Spaghetti plots of tumor burden 
in individual mice show that while untreated tumors progressed similarly quickly, 
each treatment regimen yielded variable rates of response in individuals (Figure 
8Ca-d). Tumor growth rates and drug-induced growth inhibition were independent 
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of tumor size at treatment initiation (data not shown).  When measuring tumor 
latency to 1 gram total burden per mouse, each treatment group shows increased 
latency compared to untreated controls, though the differences in group medians 
were not statistically significant (Figure 8B). 
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Figure 8.  HT-29 tumor growth is affected by bev, LP-I, and bev followed by 
LP-I compared to untreated controls.  Tumor growth inhibition assessed by 
caliper measurements represented for each treatment group compared to control, 
represented as a mixed linear model (****p<0.0001) (A).  Tumor latency to 
approximately 1 gram total tumor burden was assessed for individual mice as a 
measure of growth delay due to treatment (B).  Spaghetti plots of tumor growth in 
individual mice according to treatment with bev (C.b), LP-I (C.c), or bev followed 
by LP-I (C.d) compared to control tumors (C.a).  Bev administration is indicated by 
red lines, LP-I administration is indicated by blue lines. 
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3.4.  Bev treatment induced measurable changes in tumor blood vessels 
after two injections 
 Although treated mice received only two injections of bev, HT-29 tumors 
resected after the second 64Cu-MM-DX-929/PET showed early evidence of bev 
response.  Microvessel density (MVD) was assessed via immunohistochemical 
staining for CD34, followed by blinded analysis of tissues for vessel number and 
average diameter.  CD34 staining revealed notable differences in vessel size 
between bev-treated and control tumors (Figure 9A).  Short-term bev resulted in 
significantly smaller vessel diameters compared to untreated controls (Figure 9B). 
The total tissue area occupied by CD34+ vessels in treated tumors was 3.8% ± 
1.5% compared to 5.7% ± 1.7% in control tumors (p=0.04, Figure 10).  This 
indicates that 64Cu-MM-DX-929 in the blood pool has a very small contribution to 
the tumor tracer activity.  While the size of the vessels was noticeably altered 
following bev, the vessel density (vessels/cm3) showed no measurable difference 
between bev-treated and untreated tumors (Figure 9C).  These data would indicate 
that two injections of bev had begun eliciting an anti-vascular effect, and that the 
second 64Cu-MM-DX-929 PET was performed during the early stages of bev 
response.  Taken together with trends seen in PET, these data show that 64Cu-
MM-DX-929 PET was able to measure changes in LP delivery which were likely 
due to the early effects of bev. Importantly, while bev-induced changes in vessel 
diameter were measurable at the time of the second PET, no difference was seen 
in tumor growth rates between treated and control mice (Figure 8A).  Thus, 64Cu-
MM-DX-929 PET was able to measure early fluctuations in LP delivery due to anti-
vascular therapy, prior to any quantifiable changes to tumor morphology.   
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Figure 9.  Bev induced significant changes in blood vessel diameter early 
into treatment.  20X images of HT-29 tumor tissues stained with CD34 to identify 
blood vessels (brown) and hematoxylin to denote cell nuclei (blue) show significant 
differences in vessel size between untreated controls (A. a-c) and tumors treated 
with bevacizumab (A. d-f).  Microvessel density analysis of blood vessel diameter 
in bev-treated tumors compared to untreated controls (B).  Vessel density (vessels 
per cm3) was compared between treated and untreated tumors (C).  Data are 
presented as mean ± SD.  **p=0.0042 
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Figure 10.  Percentage of total tissue area occupied by CD34 positive vessels 
in untreated and bev treated tumors.  CD34 positive vessels were identified and 
diameters measured over a total of 1 cm
2
 of tumor.  Total vascular space per 
sample was determined by summation of the areas occupied by each vessel, as a 
percentage of total surveyed area.  This can be represented as Avasc = 
(Σ[π*(d/2)
2
]
1 n
)/cm
2
. 
 
 
 
 
 
 
 
 
 
48 
 
 
 
3.5.  64Cu-LP do not associate with macrophages and are stable in circulation 
for up to 48 hours. 
 In certain instances, macrophages have been found to take up NP such as 
liposomes (169).  When utilizing LP for imaging, significant macrophage 
engulfment of tracer-LP can confound image interpretation.  To determine the 
probability of macrophage interference with 64Cu-MM-DX-929 for PET in patients, 
we measured macrophage uptake of 64Cu-MM-DX-929 and a structurally related 
LP under clinical investigation, 64Cu-MM-302, in human whole blood.  Following 
incubation with either labeled liposome for 1 hour, blood cell populations were 
measured for radioactivity (Table 3).  Radioactivity remained in the plasma, with 
little to no activity associated with monocyte populations.  The same results were 
found when analyzing 64Cu-MM-302 in blood samples from patients receiving 
64Cu-MM-302 PET (representative patient #300-1055 presented in Table 3).  Blood 
samples taken at 1, 24, and 48 hours demonstrated that activity remained in the 
plasma for at least 48 hours (representative patient #300-1055; Figure 11A).  
HPLC analysis of LP stability was performed following 64Cu-MM-302 injection in 
patients, which demonstrated that activity remains within LP for at least 48 hours 
(representative patient #300-1055; Figure 11B).  Thus, 64Cu-MM-302 was stable 
and remained in the plasma for at least 48 hours, suggesting that 64Cu-LP PET at 
24 hours (or later) should not confounded by free 64Cu or macrophage engulfment 
of LP. 
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Table 3.  %64Cu-LP activity in human whole blood associated with blood cell 
populations. 
 
 
 
 
Figure 11.  64Cu-LP are stable in circulation and remain in plasma for at least 
48 hours.  Radioactivity in blood cell populations was assessed in patients who 
received 64Cu-MM-302 PET at time 0, 1, 24, and 48 hours.  Data from a 
representative patient (#300-1055) is shown.  Activity in blood fractions is plotted 
compared for each time point compared to whole blood (A), and HPLC analysis of 
64Cu association with LP is shown at 48 hours post-injection (B) (previously 
published in (170)). 
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4.  Discussion 
 The urgent need for precision medicine for CRC is not limited to the 
development of more sophisticated therapies, but also techniques to predict and 
monitor therapeutic efficacy. Here we have demonstrated the utility of a dynamic 
system using 64Cu-labeled liposomes for PET to non-invasively measure the early 
effects of bev therapy on LP delivery to colon tumor xenografts in mice. 
Furthermore, significant differences measured with 64Cu-MM-DX-929 PET 
between bev-treated and control tumors provided early insight into therapeutic 
outcomes in mice subsequently treated with liposomal irinotecan. 
 Clinically, the potential advantages of LP are twofold: (1) sustained and/or 
local delivery of drugs or drug combinations to tumor tissues, and (2) reduced 
toxicity profiles as normal tissues are shielded from toxic drugs (45, 171-174).  
However, heterogeneous, inconsistent, or obstructed delivery of these 
nanoparticles to tumor tissues can hamper their effectiveness, and is hypothesized 
to be a contributor to the lack of clinical success seen with many LP.  Passive 
targeting through EPR relies on specific properties of tumor blood vessels, which 
are constantly changing in response to the tumor environment and therapeutic 
intervention, particularly with antivascular agents.  While antivascular agents are 
expected to disrupt tumor vessels, there is some evidence suggesting that early 
effects of bev treatment may transiently “normalize” tumor vessels, though these 
effects are not consistent (164, 175-177).  Thus, a non-invasive means of 
measuring LP delivery to tumor tissues could provide individualized information on 
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the effect of drugs like bev on LP delivery and subsequent efficacy (17, 165, 170, 
178). 
 In these studies, we found that we could use PET to quantify changes in LP 
accumulation in colon tumor xenografts very early into bev treatment.  In mice that 
received no treatment in between PET scans, 64Cu-MM-DX-929 accumulation in 
tumors increased, indicating that LP-I were still able to reach and penetrate HT-29 
tumor tissues and elicit an effect.  While previous studies of LP-I in HT-29 tumors 
demonstrated significant anti-tumor effects when administered earlier into tumor 
progression (179, 180), the modest effects seen here were likely attributed to 
treatment initiation at late-stage disease.  Because of this, we anticipated no 
significant difference in survival among the treatment groups.  After two injections 
over the course of one week, bev had already begun eliciting anti-vascular effects, 
which were quantifiable with 64Cu-MM-DX-929 PET.  While bev treatment 
conferred therapeutic advantage in HT-29 tumors, 64Cu-MM-DX-929 PET showed 
that even short-term bev treatment began to impede liposome delivery and 
penetration.  This observation is consistent with the lack of therapeutic benefit seen 
in treating mice with LP-I which had already received bev.  
In the clinic, bev and other antivascular agents, such as ziv-aflibercept 
(Zaltrap; Regenron Pharmaceuticals Inc., Tarrytown, NY), are approved to treat 
patients with CRC.  As liposome-based therapies are introduced for this 
population, understanding the effects of antivascular agents on LP delivery could 
reduce the probability of employing incompatible drug combinations.  Furthermore, 
when designing clinical trials of LP-drug platforms for colon cancer, imaging 
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techniques could be used to non-invasively monitor changes in LP delivery over 
time, or as a result of various therapies. 
 Along with the clinical implications of bev and LP-therapy in CRC patients, 
we have been able to employ a powerful model for dynamically assessing 
modulation of LP delivery.  64Cu-MM-DX-929 PET was able to non-invasively 
quantify the effects of bev on LP delivery, which likely affected subsequent therapy 
with liposomal irinotecan injection.  This would suggest that 64Cu-MM-DX-929 PET 
may be sensitive enough to detect and monitor changes in LP delivery to solid 
tumors which may directly influence therapeutic LP efficacy.  Aspects of the tumor 
environment which affect LP distribution are dynamic, and are certain to vary 
among patient populations.  Thus, predicting and monitoring LP delivery with a 
non-invasive theranostic imaging is an invaluable tool in achieving precision 
medicine with LP for CRC patients. 
 Finally, the mission of individualized treatment plans for patients with cancer 
is one that requires a significant preclinical effort to identify diagnostic and 
therapeutic strategies.  In this study, we have demonstrated a practical system for 
measuring therapeutic modulation of LP delivery that predicted and described 
subsequent therapeutic results.  64Cu-MM-DX-929 PET may be used in preclinical 
studies of therapeutic LP to efficiently measure the effect of combination therapies, 
treatment timelines/conditions, etc. on LP delivery.  Utilizing imaging protocols with 
tracer LP like 64Cu-MM-DX-929 can quickly and non-invasively identify treatment 
conditions which improve or hinder LP delivery.  In CRC, this could mean creating 
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more avenues towards precision medicine with liposomes to improve outcomes 
for patients.  
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CHAPTER 3.  18F-FMAU PET TO EVALUATE RESPONSE TO CISPLATIN IN 
PRE-CLINICAL LUNG CANCER STUDIES 
1.  Introduction 
 With the success of 18F-FLT PET in oncological imaging, a variety of 
radiolabeled thymidine analogues have been synthesized for assessment in 
imaging studies (103).  Among these, 18F-FMAU is of particular interest.  While 
18F-FLT lacks the 3’ hydroxyl group on natural thymidine causing termination of 
DNA strand elongation, 18F-FMAU maintains a 3’ hydroxyl group and can be 
incorporated into DNA (106).  Early research into the utility of 18F-FMAU for PET 
suggested that FMAU had lower uptake in bone marrow compared to 18F-FLT 
(110).  In multiple tumor types, metastases to the bone are common, and would 
be easier to identify in scans with a tracer that demonstrates lower background in 
the marrow.  Thus, 18F-FMAU was studied as a potential alternative to 18F-FLT for 
PET of cellular proliferation in oncology (181, 182). 
Natural thymidine is incorporated into dividing cells through the DNA 
salvage pathway (183). After cellular uptake, thymidine molecules (as well as 
functional analogues) undergo phosphorylation by thymidine kinases, which 
prevents transport out of the cell.  Two forms of thymidine kinases are present in 
human cells, namely thymidine kinase 1 (TK1) and thymidine kinase 2 (TK2) (184).  
TK1 is primarily located in the cytoplasm, and its activity is strongly associated with 
the S phase of the cell cycle during nuclear DNA synthesis (185).  Conversely, 
TK2 activity is relatively low and ubiquitous compared to TK1, and TK2 is closely 
associated with mitochondrial DNA synthesis (186).  In vitro studies have 
demonstrated that FLT is predominantly phosphorylated by TK1, with strong 
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retention in actively dividing cell populations (187).  Conversely, FMAU is 
predominantly phosphorylated by TK2, and is not as highly retained as FLT in 
proliferative tissues (102).  Thus, while 18F-FLT PET is considered a means of 
measuring tumor proliferation, 18F-FMAU PET may offer a different perspective on 
cancer cell metabolism. 
Mitochondrial metabolism, a critical determinant of cellular energy 
production, is often dramatically altered in tumor cells.  Further, dynamic and 
transient shifts in mitochondrial biochemistry are being investigated as biomarkers 
for understanding tumor ATP synthesis, fatty acid oxidation, apoptosis signaling, 
synthesis of nucleotides, and more (188-190).  Heterogeneity of mitochondrial 
biology in human tumors complicates the use of mitochondrial metabolism as a 
biomarker for cancer (191).  However, measuring mitochondrial changes that 
result from treatment could provide insight into therapeutic effects on tumor 
metabolism (192, 193).  It is conceivable that, while 18F-FMAU is a less attractive 
choice for measuring proliferation with PET, 18F-FMAU PET may be useful in 
measuring mitochondria-related effects in tumors. 
Previous work in our lab, performed by Tehrani et al., provided evidence 
that FMAU uptake in tumor cells may be associated with cell stress (102).  
Following exposure to nutritional stress, prostrate and breast cancer cell lines 
exhibited increased FMAU retention while FLT retention and TK1 activity 
decreased.  FMAU retention was also increased in cells exposed to oxidative and 
reductive stresses, and correlated with mitochondrial mass measured in the cells.  
These data provide rationale for the study of 18F-FMAU PET as a measure of 
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cellular stress, particularly energy metabolism stress which occurs early into 
treatment.  We chose to measure the early effects of cisplatin treatment in human 
lung tumor models with 18F-FMAU PET. 
2. Materials and Methods 
Materials 
 NCI-H460 cells, NCI-H292 cells, and Roswell Park Memorial Institute 
(RPMI)-1640 medium were purchased from ATCC (Manassas, VA) and kept below 
15 passages following receipt.  For in vitro studies with cisplatin, cis-
Diammineplatinum(II) dichloride was purchased form Sigma Aldrich (St. Louis, 
MO).  HPLC analysis of blood samples was performed using Hypersil C18 columns 
(Thermo Fisher Scientific, Waltham, MA). Gamma spectroscopy measurements 
were acquired with a Packard Cobra II gamma counter (Perkin-Elmer Inc., 
Waltham, MA).  An R4 microPET (Concorde Microsystems, Knoxville, TN) was 
used for all animal PET scan acquisition.  PMOD Image Matching and Fusion Tool 
ver3.6 (PMOD group, Switzerland) was utilized for image registration, matching, 
and analysis.  Statistical analyses were performed using GraphPad Prism, ver7 
(GraphPad Software Inc., La Jolla, CA). 
Cell Culture 
 H460 large cell lung carcinoma cells and H292 mucoepidermoid pulmonary 
carcinoma cells cultured in RPMI-1640 medium supplemented with 5% fetal bovine 
serum and 1% penicillin/streptomycin, as described by ATCC.  Cells were kept at 
37°C with 5% CO2 and were passaged with trypsin when cells reached 
approximately 80% confluence.  Prior to inoculation in mice, cells were not 
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passaged more than ten times in culture.  Cell line identity was authenticated at 
time of all studies with the PowerPlex 16 System from Promega (Madison, WI) 
in the Applied Genomics Technology Center at Wayne State University. Analyses 
were performed using ATCC and DSMZ reported short tandom repeat loci for the 
cell lines. 
Cell Line Sensitivity to Cisplatin 
 In order to establish the difference in cisplatin sensitivity between H460 and 
H292 cells, 5 day MTT assays were performed to determine IC50 values.  Cisplatin 
(cis-Diammineplatinum(II) dichloride) was dissolved in sterile PBS and sonicated 
for 30 minutes at 37˚C until dissolved prior to generating series dilutions in culture 
medium. Cisplatin concentrations which resulted in a 50% loss of cell viability (IC50) 
after 5 days was determined independently for each cell line.  These 
concentrations of cisplatin were used for all in vitro tracer uptake assays. 
18F-FMAU Uptake in Cells Treated With Cisplatin 
 H460 and H292 cells were seeded in 6-well plates (900,000 and 1.8 million, 
respectively, due to doubling time).  Cells were allowed to reach approximately 
50% confluency (exponential growth phase) under normal culture conditions.  Cells 
were exposed to IC50 concentrations of cisplatin (as determined by 5-day MTT) or 
vehicle (PBS) in complete culture medium for 24 hours.  Following treatment, drug- 
or vehicle-containing medium was removed and cells were exposed to 18F-FMAU 
in medium for 1 hour (approximately 0.05 uCi/well), at 37 ˚C and 5% CO2.  18F-
FMAU medium was carefully collected and cells were washed three times with ice-
cold PBS (between 2-4˚C) to impede any subsequent transmembrane transport or 
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tracer phosphorylation, and remove residual free tracer.    Cells were lysed with 
1M KOH and collected, and all fractions were measured with gamma scintigraphy.  
Cellular uptake of 18F-FMAU was compared in both cell lines between cisplatin- 
and vehicle-treated cells. 
Animal Studies 
Tumor model: Cultured H460 and H292 cells grown in complete culture medium 
were used to establish subcutaneous tumor models in female SCID NCr mice 
(Charles River Labs; MA), via suspension in Matrigel prior to inoculation.  Tumors 
were maintained in serial passage, via inoculation with H460 or H292 tumor 
fragments subcutaneously by trochar, over the course of experiments.  All imaging 
studies were performed within 5 tumor passages in mice.   
MicroPET studies: Schematic representation of mouse study design is presented 
in (Figure 12).  Tumors were allowed to grow until they we approximately 250mg 
(range: 200-300mg) based on the growth rates of each tumor type.  Animals were 
randomized into their respective control (No Rx) and treatment groups (cisplatin). 
All mice were imaged with microPET before and 24±2 hours after a single injection 
of cisplatin.  Scans were compared for changes in tracer uptake in tissues of 
interest.  Mice were euthanized under anesthesia with whole blood and tissues 
collected after the second PET for HPLC analysis and biodistribution 
measurements, respectively.   All mice were weighed and observed daily for the 
duration of the study. Tumors were measured by caliper 2-3x/weekly with the 
formula [volume (mg) = length (mm) x width2 (mm2)/2] used to calculate tumor 
mass.   
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Tracer preparation and injection: 18F-FMAU was synthesized as described 
previously (103).  To achieve similar injected activity and volume, 18F-FMAU was 
diluted in sterile saline when necessary.  Mice were administered 200-300 
uCi/injection intravenously (IV) within a 0.1 to 0.3 ml volume range.  
Drug preparation: Cisplatin was freshly prepared for each injection from stock 
diluted with 0.9% sterile saline, pH 6.0 and injected IV at 11 mg/kg in a volume of 
approximately 0.2ml/20g mouse.  Cisplatin injections were administered 
immediately following the first PET scan, after the mouse had fully recovered from 
anesthesia.  Cisplatin treatment consisted solely of a single injection, and effects 
were assessed via PET after 24 ± 2 hours. 
All animal studies were approved by and performed in strict accordance with the 
policies of the Institutional Animal Care and Use Committee (IACUC) at Wayne 
State University.  
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Figure 12.  Schematic representation of FMAU mouse study design.  Mice 
bearing H460 or H292 tumors were randomized to treatment groups, with half of 
the mice receiving IV cisplatin following the first PET.  All mice were scanned again, 
approximately 24 hours after the first PET. 
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Animal Imaging with 18F-FMAU PET 
 Following receipt of 18F-FMAU mice received approximately 200-300 µCi of 
18F-FMAU intravenously via the tail vein.  Whole body PET images were acquired 
one hour after IV administration of 18F-FMAU. Dynamic images of representative 
animals from each treatment group were acquired immediately after tracer 
injection for 60 minutes, followed by a 10 minute whole body scan.  Anesthesia for 
image acquisition was induced with 3% inhaled isoflurane prior to placement on 
the scanner, and maintained during scanning with 2% isoflurane.  Mice were 
imaged in a prone position on the scanner bed with heating to maintain body 
temperature. 
 Attenuation correction based on routine transmission scans was performed 
on the whole body microPET images.  Images were reconstructed by applying an 
iterative ordered-subsets expectation maximization 2-dimensional algorithm (167) 
and corrected for scatter.  These parameters yield an isotropic spatial resolution 
of approximately 2mm in full width at half maximum (168).  Prior to study, a 
phantom for 18F was scanned to calculate conversion from counts/pixel/minute to 
kBq(μCi)/cm3. 
PET/CT Image Registration and Analysis 
 PET and CT images were registered and aligned using the PMOD Image 
Matching and Fusion Tool ver3.6 (PMOD group, Switzerland).  Regions of interest 
(ROIs) were defined manually on individual planes of the PET.  3-dimensional 
volumes of interest (VOIs) were generated from the stacked ROIs of the tissue of 
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interest.  Activity in the VOIs, as detected by PET in kBq(μCi)/cm3, as well as 
injected dose and body weight were used to calculate standardized uptake values 
(SUV).  SUVmax values were determined by averaging the max pixel value within 
each of the three hottest consecutive ROIs of a tissue, and normalizing to injected 
dose and body weight.  
Whole Body Tissue Distribution of 18F-FMAU 
 18F-FMAU retention in resected tissues was assessed by gamma 
spectroscopy.  Briefly, following the second PET scan, mice were sacrificed and 
tissues harvested.  Resected tissues included tumor, liver, heart, lung, intestine, 
stomach, kidney, spleen, and whole blood.  Serum from whole blood of 
representative animals of each treatment group was subjected to HPLC analysis.  
Tissues were washed, weighed, and activity was measured for one minute on a 
gamma counter.  Activity in tissues was decay corrected to time of injection and 
normalized to tissue weight (kBq/cc).  Activity per gram of tissue was calculated 
based on the injected dose of 18F-FMAU.  Tissue biodistribution was compared 
between mice treated with cisplatin and untreated controls to ensure that cisplatin 
treatment was not affecting systemic distribution or retention of 18F-FMAU. 
HPLC of Circulating 18F-FMAU in Whole Blood  
 Following the second 18F-FMAU PET, whole blood was drawn from animals 
post-sacrifice to determine if 18F-FMAU had been metabolized during circulation 
time.  Samples representing treated animals and untreated controls were selected 
for HPLC analysis of 18F-FMAU, as previously described (102).  Briefly, sera 
collected from whole blood was loaded onto a Hypersil C18 column with 6% 
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Acetonitrile, 10mM NaOAc, and allowed to run at a flow rate of 1 ml per minute.  
0.5 ml fractions were collected and 18F activity was measured via gamma 
scintigraphy.  Curves generated from the HPLC of blood samples were compared 
to results from running a small aliquot of pure 18F-FMAU as received prior to 
injection. 
Statistical Analysis 
 Statistical analyses were performed using GraphPad Prism 7 (GraphPad 
Software Inc., La Jolla, CA).  Data are presented as the mean ± standard deviation, 
unless otherwise stated.  Comparisons of PET SUV data were performed using 
two-sample Student’s t-test. A p-value of <0.05 was considered statistically 
significant. 
3.  Results 
3.1.  Changes in 18F-FMAU uptake in lung tumor cells after cisplatin treatment 
differ based on cisplatin sensitivity 
 To assess the capacity of 18F-FMAU to measure early response to cisplatin 
treatment, we sought to compare lung cancer cell lines with differing sensitivities 
to cisplatin.  Multiple non-small cell cancer cell lines were subjected to MTT 
following treatment with cisplatin to determine relative sensitivity (data not shown).  
Of these, H460 cells and H292 cells were selected for further study, as these cells 
demonstrated a measurable difference in sensitivity to cisplatin.  IC50 values were 
determined independently for H460 and H292 cells by exposing the cells to a 
series of cisplatin concentrations for 5 days, followed by MTT (Figure 13).  H460 
cells were identified as being more sensitive to cisplatin treatment (IC50 = 0.06 nM) 
than H292 cells (IC50 = 0.2 nM).  The determined IC50 values were used throughout 
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all of the in vitro studies, representing the concentration of cisplatin which, after 5 
days, would result in 50% cell death. 
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Figure 13.  H460 cells are more sensitive to cisplatin-induced cell killing than 
H292 cells.  Assessment of cell viability of H460 and H292 cells was assessed by 
MTT after 5 days of exposure to cisplatin concentrations in complete culture 
medium.  IC50 values were determined as the concentration of cisplatin capable of 
causing a 50% loss of viability after 5 days.  IC50 values were determined 
independently for each cell line, by which H460 cells were determined to be 
“cisplatin-sensitive” and H292 cells “cisplatin-resistant”. 
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 Cellular uptake assays of 18F-FMAU were performed with H460 and H292 
cells following exposure to cisplatin or vehicle (PBS) in complete culture medium.  
Cells were treated with determined IC50 concentrations of cisplatin for 24 hours, 
and subsequently exposed to cisplatin-free, complete culture medium containing 
18F-FMAU for 1 hour.  Following multiple washes, 18F-FMAU retention in cells was 
assessed via gamma scintigraphy.  Interestingly, little change was noted in 18F-
FMAU retention in sensitive H460 cells following exposure to cisplatin (Figure 
14A), while resistant H292 cells demonstrated significantly increased retention 
with treatment (Figure 14B). As expected, IC50 concentrations determined with 5 
day MTT induced negligible reductions on cell number and viability after 24 hours, 
with H460 and H292 cells maintaining 100 ± 2% and 96 ± 2% viability respectively, 
as assessed by Trypan Blue measurements (data not shown).  This indicates that 
differences seen in 18F-FMAU uptake in cells between treated and untreated cells 
were not the result of significant differences in viability. 
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Figure 14.  After 24 hours of cisplatin treatment 18F-FMAU uptake increased 
in H292 cells but not H460 cells.  Plated cells were exposed to 18F-FMAU for one 
hour following 24 hours  of cisplatin treatment (at determined IC50 concentrations) 
to measure the effect of treatment on tracer retention compared to vehicle controls.  
Following washes, cell-associated 18F-FMAU in treated cells was quantified and 
normalized to uptake in untreated controls.  (****p<0.0001). 
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3.2. Significant decreases in 18F-FMAU uptake were observed in H460 
xenografts but not H292 xenografts after 24 hours of cisplatin treatment 
in mice 
 Tumor retention of 18F-FMAU following 24 hours of cisplatin treatment was 
assessed in vivo with microPET of female SCID NCr mice bearing H460 or H292 
xenografts. Mice were scanned at baseline, prior to any treatment, 1 hour after 
injection of 18F-FMAU.  Immediately following the scan, half of the mice in each 
tumor group received a single injection of cisplatin at 11 mg/kg.  All mice were 
scanned again with 18F-FMAU PET 24 ± 2 hours after the baseline scan.  Notable 
uptake was seen in tumor tissues, as well as in the bladders of some mice, 
indicative of clearance.  Low uptake was seen in muscle tissue, which was 
selected for background measurements of 18F-FMAU uptake.  SUVmax values were 
compared between baseline scans and post-treatment scans to generate 
%ΔSUVmax values for each individual tumor. 
 PET images revealed robust changes in 18F-FMAU SUVmax in treated H460 
(cisplatin-sensitive) tumors, with a mean change of -40.0% (range of -21.1% to 
52.5%).  This was statistically significant (****p<0.0001) compared to untreated 
H460 tumors, which showed negligible change in SUVmax 24 hours after baseline, 
with a mean of 3.73% (range of -7.4% to 12.4%) (Figure 15).   Cisplatin-resistant 
H292 tumors, on the other hand, showed no significant change in SUVmax between 
PET scans, in both treated (mean change of -5.39%, range of -26.1% to 27.7%) 
and untreated tumors (mean change of -1.03%, range of -30.6% to 33.0%).  
SUVmax data were validated by assessing changes in SUVmean of isocontours 
representing the hottest 50% of the tumor max pixel, which demonstrated the same 
trends seen with SUVmax.  Cisplatin treatment did not induce critical toxicities in 
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any treated mice, although constipation was noted in some treated mice during 
necropsy after sacrifice on the second scan day. 
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Figure 15.  Cisplatin-treated H460 tumors in mice showed significant 
reductions in 18F-FMAU uptake compared to H292 tumors imaged with PET.  
18F-FMAU PET scans were acquired before and after 24 hour treatment with a 
single injection of cisplatin in mice bearing H460 or H292 tumor xenografts.  
Uptake in tumor tissues was quantified as SUVmax values, and changes in uptake 
following the treatment period were calculated as %ΔSUVmax.  (****p<0.0001). 
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 18F-FMAU PET images of H460 tumors visualized lower tracer uptake 24 
hours after a single dose of cisplatin compared to untreated controls (Figure 16).  
In nearly all treated H460 tumors, this effect was evident across the entire volume 
of the tumor, both in the center of the mass and in the tumor periphery.  In 
untreated H460 tumors, changes in tracer uptake were negligible to modest (mean 
change of -3.73%, range of -7.4% to 12.4%).  Often, untreated tumors showed 
slight increases in 18F-FMAU uptake, but this was considered within the confines 
of 18F-FMAU PET reproducibility, as previously described (194).  Unlike H460 
tumors, PET of 18F-FMAU uptake in cisplatin-resistant H292 tumors showed no 
consistent trend that could discriminate between treated and untreated tumors 
(p=0.9850) (Figure 17). 
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Figure 16.  18F-FMAU PET scans of mice bearing H460 tumors before and 
after cisplatin treatment.  Representative 18F-FMAU scans of mice bearing H460 
(cisplatin-sensitive) xenografts at baseline (left) and after 24 hours (right).  
Treatment with a single injection of cisplatin induced robust reductions in 18F-
FMAU uptake in tumors (indicated in white) (A), compared to changes in uptake 
seen in untreated mice (B).  PET image color scale was calculated as follows: ½ 
background average  tumor max pixel. 
73 
 
 
 
 
Figure 17.  18F-FMAU PET scans of mice bearing H460 tumors before and 
after cisplatin treatment.  Representative 18F-FMAU scans of mice bearing H292 
(cisplatin-resistant) xenografts at baseline (left) and after 24 hours (right).  
Treatment with a single injection of cisplatin induced negligible changes in 18F-
FMAU uptake in tumors (indicated in white) (A), compared to changes in uptake 
seen in untreated mice (B).  PET image color scale was calculated as follows: ½ 
background average  tumor max pixel. 
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3.3.  Systemic distribution and clearance of 18F-FMAU was not affected by 
cisplatin treatment 
 Representative mice from each treatment group was measured with 60-
minute dynamic scans after tracer injection to monitor 18F-FMAU distribution and 
clearance.  Time activity curves describing activity over time were generated to 
determine if any differences in clearance were observed in tumor, liver, and muscle 
between treated and untreated mice (Figure 18A and B). 
 To ensure that cisplatin did not alter systemic 18F-FMAU distribution in a 
way which would affect tumor uptake, radioactivity was measured in bulk resected 
tissues.  Following the second PET scan, mice were euthanized and resected 
tissues of interest were measured with gamma scintigraphy, with activity measured 
as %i.d./cc.  Treated mice maintained slightly higher levels of activity in whole 
blood compared to untreated mice.  In animals bearing H460 tumors, this was 
measured as mean normalized %i.d./gram of 2.04% ± 0.84% in blood samples of 
treated mice compared to 1.19% ± 0.54% in control mice.  In mice bearing H292 
tumors, normalized %i.d./gram of blood samples was measured as 1.31% ± 0.40% 
in treated mice compared to 0.84% ± 0.43% in untreated mice.  However, these 
differences were not significant for mice bearing H292 or H460 tumors (p=0.52 and 
0.53, respectively) (Figure 18C and D).  In all groups, non-tumor tissues exhibited 
no significant difference between mice treated with cisplatin compared to untreated 
mice.  This suggests that systemic tissue retention of 18F-FMAU was not 
significantly altered by cisplatin treatment in a way which could confound tumor 
analysis.  Resected H292 tumors showed no difference in activity between 
cisplatin-treated and untreated tumors.  Similarly to the results seen by PET, 18F-
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FMAU retention in H460 tumors treated with cisplatin was significantly lower than 
untreated H460 tumors (*p=0.017).  
 
 
 
 
 
 
76 
 
 
 
 
Figure 18.  Cisplatin treatment did not alter clearance or biodistribution of 
18F-FMAU in mice.  Representative curves of tracer uptake over time, as 
measured by 60-minute dynamic scan, in cisplatin-treated mice bearing H460 
tumors demonstrate that 18F-FMAU clearance is not altered in liver or muscle 
tissues (A) compared to tissues in untreated mice (B).  Uptake was reduced in 
H460 tumors, consistent with whole body PET data of 18F-FMAU uptake following 
cisplatin.  Measured activity in bulk resected tissues from treated mice bearing 
H460 or H292 tumors was normalized to untreated controls.  Relative activity 
suggests that cisplatin treatment does not significantly alter systemic 
biodistribution of 18F-FMAU.  As seen in PET, H460 tumors showed a significant 
reduction in 18F-FMAU retention after cisplatin treatment compared to controls 
(*p=0.17).  While 18F-FMAU in the blood pool increased after cisplatin treatment, 
these effects were not determined to be statistically significant in mice bearing 
either H460 or H292 tumors (p=0.52 and 0.53, respectively) 
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3.4.  18F-FMAU metabolism was not altered by cisplatin treatment 
 Following euthanasia, serum of whole blood samples from representative 
animals in each treatment group was analyzed with HPLC.  Fractions were 
measured with gamma scintigraphy to detect 18F-FMAU and any relevant 
metabolites, as represented by peaks in corresponding fractions.  Samples were 
compared to HPLC curves of pure 18F-FMAU samples retained prior to animal 
injections (Figure 19A).  The majority of activity detected in the serum 
corresponded to unmetabolized 18F-FMAU, with small amounts of metabolite 
noted as separate peak(s).  Comparison of serum from mice treated with cisplatin 
(Figure 19C) to serum from untreated mice (Figure 19B) suggests that a single 
injection of cisplatin does not cause any measurable change in 18F-FMAU 
metabolism.  Thus, changes in 18F activity in tumors is unlikely to be caused by 
uptake of functionally different metabolites which retain 18F conjugation. 
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Figure 19.  18F-FMAU metabolites represent a negligible fraction of 18F-FMAU 
detected in the blood and are not significantly altered by cisplatin treatment.  
HPLC analysis of serum from cisplatin-treated and control mice was performed 
after sacrifice following the second PET scan.  Peaks of activity in resulting 
fractions were detected with gamma-scintigraphy, and were compared to curves 
generated from HPLC of a sample of synthesized 18F-FMAU (A).  Although trace 
amounts of metabolites are seen in serum, the majority of activity corresponds with 
18F-FMAU in treated (B) and untreated mice (C). 
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4.  Discussion 
 As a functional analogue of thymidine like 18F-FLT, 18F-FMAU was originally 
tested as a marker for proliferation in tumor imaging (181, 182, 195).  However, 
FMAU phosphorylation has been shown to be primarily phosphorylated by TK2.  
Unlike TK1, TK2 activity is not cell-cycle dependent, and is closely associated with 
mitochondrial DNA synthesis.  While this understanding confounds the association 
between 18F-FMAU retention and cellular proliferation, it provides new 
opportunities for the use of 18F-FMAU PET. 
In this work, we present evidence that 18F-FMAU PET may be useful in 
identifying early response to chemotherapy in non-small cell lung tumors.  Previous 
work in our lab had demonstrated that mild cellular stress, such as nutritional 
deprivation, could induce a transient increase in FMAU uptake and retention in 
multiple cancer cell lines (102).  These cells demonstrated increased TK2 activity 
and FMAU retention, while TK1 activity and FLT retention dropped.  This 
suggested that, while proliferation (and associated FLT phosphorylation) slowed 
during cellular stress, a “flare” effect may be observed in FMAU retention which 
could indicate a stress response.  Unlike nutritional or oxidative pressures, cisplatin 
treatment induces a very strong genotoxic effect.  Interestingly, in vitro uptake 
assays of 18F-FMAU showed a flare in uptake following cisplatin treatment in 
cisplatin-resistant H292 cells (Fig. 2B).  This effect was not seen in cisplatin-
sensitive H460 cells.  Although unexpected, increased FMAU retention in H292 
cells could be indicative of a cellular stress response—one which is perhaps more 
robust in overcoming the effects of cisplatin. 
80 
 
 
 
This “flare” effect was not seen in mouse studies of 18F-FMAU PET which 
utilized the same tumor cell lines (Fig.3).  However, an extremely significant drop 
in 18F-FMAU retention was measured in H460 tumors treated with cisplatin 
compared to controls, while no difference was seen with cisplatin treatment in 
H292 tumors.  The reduced uptake in the H460 tumors, which were more likely to 
respond to cisplatin treatment the H292 tumors, occurred within 24 hours of a 
single injection of cisplatin.  This was well before any measurable changes in tumor 
size were evident, indicating that 18F-FMAU PET was sensitive enough to measure 
very early changes in H460 metabolism induced by cisplatin.  
It is important to note that, while a flare was seen in H292 cells in vitro, this 
effect was measured with a relatively high dose of cisplatin (IC50 value as 
determined by MTT).  In vivo, the therapeutic dose is limited by systemic 
bioavailability and toxicity.  Thus, the cisplatin dose to which the H292 tumors were 
exposed in mice may not have been powerful enough to alter tumor cell 
metabolism and 18F-FMAU retention.  Realistically, chemotherapeutic doses in the 
clinic often fall short of the amount of drug required to kill tumors. 
To better understand these data, we will perform protein analyses of both 
cell lines to measure TK2 presence in the presence or absence of cisplatin.  This 
should ensure that TK2 protein levels are not affected by cisplatin in a way which 
could confound the imaging data.  Further, we may pursue measurements of 
mitochondrial mass in each cell line before and after cisplatin treatment, to 
ascertain the role of mitochondrial proliferation in FMAU uptake in these cells.  This 
could provide insight into the differences seen in FMAU uptake following cisplatin 
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treatment of these cells, as well as the inconsistencies observed between cell 
studies and animal PET studies. 
While we did not measure a flare with 18F-FMAU uptake in either tumor in 
response to cisplatin, 18F-FMAU PET was able to differentiate between cisplatin-
sensitive and cisplatin-resistant tumors.  Moreover, the sensitive tumors were 
distinguishable 24 hours into treatment, after a single dose.  We believe that this 
is compelling evidence for the use of 18F-FMAU PET in predicting non-small cell 
lung cancer response early into cisplatin treatment.  To better understand the 
potential of this tracer for oncological imaging, further study of 18F-FMAU PET in 
tumors is necessary. 
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CHAPTER 4.  SUMMARY 
 Cancer patients face a myriad of challenges in combating tumors, which are 
often as unique as the person harboring them.  Oncological PET offers a variety 
of opportunities for researchers and clinicians to use non-invasive imaging in the 
personalization of cancer treatment.  Although many forms of imaging can provide 
information on tumor location, size, and general morphology, PET can measure 
metabolic and biochemical parameters of tumors.  Due to the impressive sensitivity 
of PET, thoughtfully designed tracers can be used to quantify specific processes 
in tissues.  In the case of PET for tumors, information about metabolic activity or 
cellular behavior can define or drastically alter therapeutic strategies selected to 
treat a cancer. 
 Information about tumor biochemistry is assessed non-invasively with PET 
imaging.  Unlike more traditional means of tumor profiling, such as tissue biopsy, 
PET does not require invasive procedures and provides information about the 
entire tumor or multiple tumor within an individual.  This makes longitudinal 
monitoring of tumor behavior much easier on the patient, and can be used to 
measure changes in tumor activity over time or as a result of therapy.  Subtle 
changes in tumor behavior can be detected with PET well before changes in 
overall morphology are measurable, making PET an ideal means of detecting early 
response to treatment.  The heterogeneic nature of tumors leads to a wide variety 
of responses to conventional or experimental therapies.  Early detection of 
response in patient populations could identify patients who are likely to respond to 
a therapy and, more importantly, those who are unlikely to respond.  Patients with 
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tumors predicted to be resistant can move on to other strategies before there is 
obvious growth or spread of the tumor and thus avoid further ineffective treatment 
regimen. 
 PET has become an important method for measuring and monitoring 
nanoparticle delivery to solid tumors, particularly in preclinical studies.  Successful 
delivery of nanoparticles to solid tumor tissue is necessary for the successful 
implementation of nanoparticle-based cancer treatments.  Unfortunately, 
nanoparticle delivery is highly variable in patient tumors, which has led to an effort 
in identifying therapeutic strategies for manipulating nanoparticle delivery as 
needed.  We have shown that PET with radiolabeled nanoparticles is an elegant 
means to not only measure nanoparticle delivery to tumors, but to monitor changes 
induced by combination therapy.  We found that bevacizumab-induced changes in 
vascularity of colon tumor xenografts was able to significantly alter nanoparticle 
delivery after only one week of treatment.  Further, these effects were detectable 
by PET with a 64Cu-labeled liposome.  By utilizing tracer nanoparticles that mimic 
drug-loaded nanoparticles, researchers can utilize PET to define and monitor 
therapeutic strategies to augment nanoparticle delivery to solid tumors.  
 The biochemistry of the tracers used for PET define the type of information 
that is acquired with a PET scan.  In the clinic, the most commonly used tracers 
are small molecules which specifically integrate into biological processes of 
interest.  Similarly, 18F-FMAU is a thymidine analogue studied for tumor imaging 
with PET.  In our studies of both cells and mouse models of lung cancer, we found 
that changes 18F-FMAU uptake may be indicative of tumor response to treatment 
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with cisplatin.  18F-FMAU uptake in cisplatin-responsive tumors dropped 
dramatically during treatment, while resistant tumors showed little change in tracer 
uptake.  Importantly, these changes were seen within 24 hours of treatment 
initiation, and only one injection of cisplatin.  18F-FMAU PET was able to clearly 
differentiate between resistant and sensitive tumors very early into treatment.  This 
supports the promise of PET for imaging early response to treatment in lung 
tumors undergoing chemotherapy. 
 In conclusion, the advantages of oncological PET imaging extend far 
beyond the limits of defining tumor morphology. PET can be utilized to detect 
treatment-induced changes in tumor behavior with tracers that range from small-
small molecule to nanoparticles.  In the era of targeted therapies and precision 
medicine, PET is a powerful tool to measure, monitor, and predict tumor response 
to treatment.  In this way, PET can help physicians select better therapeutic 
strategies that are tailored to the specific needs of each individual patient. 
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ABSTRACT 
PET IMAGING OF EARLY THERAPEUTIC RESPONSE IN SOLID TUMORS 
by 
STEPHANIE J. BLOCKER 
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Advisor: Dr. Anthony F. Shields 
Major: Cancer Biology 
Degree: Doctor of Philosophy 
An important pillar of precision medicine for oncology is the ability to identify 
patients who respond to treatment early into their therapy. Positron emission 
tomography (PET) allows physicians and researchers to measure changes in 
tumor behavior prior to noticeable differences in morphology. 
Objective: Determine the utility of multiple tracers for PET in assessing 
early changes in tumor activity that result from treatment. 
Methods: Two tracers for PET were studied. 64Cu-labeled liposomes were 
used to assess changes in liposome delivery two solid colon tumors early into 
treatment with bevacizumab (Bev). 18F-FMAU thymidine analog (1-(2'-deoxy-2'-
fluoro-beta-D-arabinofuranosyl)thymine), was utilized to detect early response to 
cisplatin treatment in non-small cell lung tumor models. Scans were analyzed 
before and after short-term therapy to determine changes in tracer retention which 
suggest therapeutic response. 
Results: In each study PET was able to detect changes in tumor behavior 
which occurred early into treatment. After two injections of Bev over one week, 
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liposome delivery was significantly reduced as measured by PET. In lung tumors, 
24 hours of cisplatin treatment induced significant drops in 18F-FMAU retention in 
cisplatin sensitive tumors compared to resistant tumors. 
Conclusion: PET imaging with a variety of tracers can provide information 
about tumor response to a broad spectrum of treatments. Thus, PET is a powerful 
tool for personalized therapy of cancer. 
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